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Summary
This investigation was undertaken to study the mechanism 
of the effects of adrenergic and ischaemic challenge on the 
activities of lipid metabolising enzymes in perfused rat 
hearts. The activation state of phosphorylase was 
measured for comparison with the activities of triglyceride 
lipase (TGL) and glycerol 3-phosphate acyltransferase (GPAT).
Perfusion with adrenaline increased TGL activity and 
decreased GPAT activity. This inhibition of GPAT could be 
reversed on incubation of heart homogenates under 
dephosphorylation conditions and mimicked by incubation 
with cAMP-dependent protein kinase. Adrenaline inhibited 
microsomal GPAT activity only; the mitochondrial activity 
was unchanged. Homogenization of hearts in NaF enhanced the 
adrenaline-induced depression of microsomal GPAT activity.
Both perfusion of hearts and incubation of heart extracts 
with the protein kinase C activator 12-0-tetradecanoyl phorbol 
13-acetate (TPA) inhibited microsomal GPAT activity; TGL 
activity was unaffected. Incubation of heart extracts under 
dephosphorylation conditions reversed the TPA-induced decrease 
in GPAT activity. Perfusion with TPA caused an activation 
of phosphorylase.
Perfusion with adrenaline and TPA produced identical 
changes in enzyme activity to those seen with TPA alone.
Induction of ischaemia activated TGL and inhibited 
GPAT activity (in homogenate or microsomal fraction).
This effect has been attributed to cAMP-dependent phosphoryl­
ation. On reperfusion, TGL activity returned to control 
values but GPAT activity was further depressed.
Phosphorylase activity increased during ischaemia and, on 
reperfusion,a further increase occurred. These changes 
are the mirror image of the changes in GPAT activity.
2+Preperfusion of hearts with Ca -antagonists prevented 
the reperfusion, but not ischaemia, induced inhibition of 
GPAT.
Induction of ischaemia in isolated hearts from diabetic
rats produced similar changes in enzyme activity to those
occurring in normal hearts. However, there was no further
inhibition of GPAT or activation of phosphorylase on
reperfusion of diabetic hearts. Since, in normal hearts,
2 +Ca antagonists prevented the reperfusion-induced fall in
2+GPAT activity, this suggests that Ca uptake during 
reperfusion is attenuated in diabetic hearts.
AIMS
The object of the work performed in this thesis 
was to investigate mechanisms involved in regulating the 
activities of lipid metabolizing enzymes (GPAT, TGL and 
CAT) during ischaemia and reperfusion of isolated perfused 
hearts from normal and diabetic rats.
(1) Heathers (1985) found evidence for an a^-adrenergic
activity upon reperfusion of previously ischaemic hearts
which caused a decrease in GPAT activity without affecting
TGL activity. Here, the mechanism of this a^-effect was
2+mvestigated by use of Ca antagonists and phorbol esters
(activators of PKC): two possible mediators of a^-action
24-are an increase in [Ca and activation of PKC.
(2) Hearts from diabetic animals are known to have elevated 
levels of triglyceride. Therefore, control of enzymes of 
triglyceride metabolism may be altered in diabetes.
Enzyme activities were also measured during ischaemia and 
reperfusion to determine whether similar changes occurred 
to those found in non-diabetic hearts.
Increases in the concentration of fatty acid 
metabolites have been associated with arrhythmias occurring 
during ischaemia; diabetic hearts have an elevated level of 
such metabolites and an increased incidence, of ischaemia- 
induced arrhythmias. Knowledge of the control of enzymes 
involved in the generation and removal of fatty acid 
metabolites may help further our understanding of the 
mechanisms involved in arrhythmogenesis.
INTRODUCTION
11.1 Myocardial Lipid Metabolism
The heart is a constantly contracting muscular tissue 
and therefore a centre of intense metabolic activity. The 
substrates needed to provide energy for mechanical and 
electrical activity are supplied largely by the blood. 
However, the heart contains glycogen and lipid (triglyceride) 
stores which can be used when exogenous substrate supply is 
limited (for example during ischaemia) or when the heart is 
stimulated with catecholamines ( when energy demand exceeds 
substrate supply from the blood).
a) Exogenous substrates
Fatty acids are utilized in preference to glucose; 
fatty acid oxidation comprising 60-70% of oxidative 
metabolism (Neely et al., 1972). Non-esterified (free)
fatty acids depress glucose utilization by inhibiting 
pyruvate dehydrogenase activity, due to formation of acetyl- 
CoA units derived from fatty acid oxidation (Randle et al., 
1970).
Fatty acids are available to the heart directly as 
albumin complexes in blood or as the products of lipoprotein 
lipase activity at the myocardial cell surface upon 
circulating chylomicra and very low density lipoproteins.
2The heart also utilizes lactate, pyruvate, ketones 
and amino acids. These are not quantitatively major 
substrates but may become important under certain conditions 
e.g. in the normal heart during ischaemia and as ketone 
bodies in uncontrolled diabetic episodes.
b) Endogenous substrates
Triglyceride is the major energy store of the 
myocardium: substrate-free perfusion of the isolated rat
heart results in depletion of glycogen stores within 5 mins. 
whereas contraction can be maintained by endogenous lipid 
for up to 4b mins. (Shipp et al., 1964). Catecholamines 
can stimulate endogenous lipolysis - this can be measured 
as increased rates of glycerol release (Christian et al., 
1969; Severson et al., 1980) or a decreased tissue level 
of triglyceride (Crass et al., 1975). Exogenous glucose 
has little effect on endogenous triglyceride utilization but 
exogenous fatty acids inhibit endogenous lipolysis (Crass 
et al., 1975), as do elevated levels of endogenous fatty 
acids or long chain acyl CoA (Neely et al., 1972).
c) Intracellular metabolism
Myocardial metabolism is highly aerobic; mitochondria 
comprise approximately 30% of cardiac cell volume (Sobel, 
1974). Energy generating pathways involve the normal routes 
of carbohydrate and lipid metabolism: (i) glucose is
3Legend to Figure 1.1
1. Glucose kinase, hexokinase
2. Phosphoglucose isomerase
3. Phosphoglucomutase
4. Phosphofructokinase
5. Aldolase
6. Triosephosphate isomerase
7. Glyceraldehyde-3-phosphate dehydrogenase
8. Phosphoglycerate kinase
9. Phosphoglyceratemutase
10. Enolase
11. Pyruvate kinase
12. Lactic dehydrogenase
13. Pyruvate dehydrogenase
4Figure 1.1
The glycolytic pathway
Glucose
A T P _  
ADP £-
glucose-6-phosphate
11=
glucose-l-phosphate
fruetose-6-phosphate
ATP.
ADP 4-
fructose-1,6-diphosphate
dihydroxyacetc^S.
phosphate
glyceraldehyde 
3-phosphate ^
•f
NAD
NADH ♦ H
1,3-diphosphoglycerate 
1 ADP
'ATP
3-phosphoglycerate
/It
2-phosphoglycerate
lojt
phosphoenol pyruvate 
 ADP
11
pyruvate
>ATP
12
NADH NAD
4-
♦ H
— lactate
^ inner mitochondrial
I ‘X . membrane____________
pyruvate
CoASH, NAD
^  ~ * CO , NADH ♦ H
acetyl CoA 2
5phosphorylated to glucose 6-phosphate which can either be 
stored as glycogen or enter glycolysis (see Figure 1.1) to 
produce pyruvate. The latter can enter the citric acid 
cycle (via pyruvate dehydrogenase activity) or be reduced 
to lactate (under conditions of reduced oxygen supply)
(Neely and Morgan, ly74). (ii) fatty acids (from 
endogenous or exogenous sources) are activated to fatty 
acyl-CoA thioesters which enter mitochondria via the 
carnitine cycle (Figure 1.2). The resultant mitochondrial 
acyl CoA esters undergo 8-oxidation (Figure 1.3) to produce 
acetyl CoA units which enter the citric acid cycle 
(Figure 1.4).
Lipid synthesis is also active in the myocardium acyl 
CoA esters react with glycerol 3-phosphate derived from 
glycolysis to form triglycerides (Denton and Randle, 1965) 
or can be used for synthesis of membrane phospholipids 
(Dawson, 1966).
i) Lipases
Several discrete lipase activities have been described 
in the mammalian heart including lipoprotein lipase, mono- 
di- and tri-glyceride lipases and an acid lipase (Stam et al., 
1986).
A neutral triglyceride lipase (TGL) (EC 3.1.1.3) 
controls the rate limiting step of endogenous triglyceride 
hydrolysis (Figure 1.5); hydrolysis is completed by the 
sequential action of diglyceride and monoglyceride lipases.
6
Figure 1.2
Lipid metabolism in cardiac muscle
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7Figure 1.3
B-oxidation of fatty acids
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The citric acid cycle
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9Hulsmann et al (1981), suggested that both acid and 
neutral lipases may contribute to endogenous lipolysis. 
However, since chloroquine (a lysosomotropic agent which 
inhibits the acid lipase) did not decrease glycerol output 
from perfused rat hearts (Rosen et al., 1981b; Severson 
et al., 1980), it can be concluded that it is the neutral 
TGL activity which essentially determines the rate of 
cardiac lipolysis.
The nature of this neutral lipase has been the subject 
of much controversy; in hearts perfused with heparin to 
remove vascular lipoprotein lipase (LPL), a residual LPL 
activity remains which could either be an intracellular 
storage pool or a soluble precursor (Hulsmann et al., 1982). 
However, several workers have identified a neutral lipase 
with properties distinct from those of LPL (Ramirez et al., 
1985; Goldberg and Khoo, 1985). Thus, unlike LPL, TGL is 
not stimulated by heparin nor is it inhibited by NaCl and 
protamine sulphate. It is inhibited by NaF. Also unlike 
LPL, it is not activated by apolipoprotein CII.
In previous work from this laboratory, Al-Muhtaseb 
(19 82) developed an assay whereby LPL and TGL could be 
distinguished. This was based on the assay pH, type of 
buffer and the presence or absence of serum (see "Methods" 
section for details).
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Figure 1.5
Triglyceride hydrolysis
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ii) Enzymes of triglyceride synthesis
The pathway of mammalian triglyceride synthesis was
first described by Kennedy et al. (1961). The overall
pathway of triglyceride and phospholipid synthesis is shown
in Figure 1.6. (review, Bell and Coleman, 1983). Fatty
acids are activated to fatty acyl CoA thioesters by one of
several fatty acyl CoA (FA-CoA) synthetases, depending on
acyl chain length. Cytosolic FA-CoA esters can then
undergo either esterification to form glycerolipids or
mitochondrial oxidation. The initial, rate limiting step
in triglyceride synthesis is catalysed by glycerol 3-phosphate
acyl transferase (GPAT) (see next section). The reaction
proceeds to 1,2-diacylglycerol phosphate (phosphatidate)
by the action of 1-acyi glycerol 3-phosphate (lysophosphatidate)
acyltransferone. The next enzyme, phosphatidic acid
2+phosphatase (PPH) exists in an Mg -dependent and an 
2+Mg -independent form (depending on cellular location). 
Diacylglycerol acyltransferase catalyses the final step in 
triglyceride synthesis and is the only enzyme in the 
pathway unique to triglyceride synthesis.
Glycerol 3-phosphate acyl transferase (GPAT) (EC 2.3.1.15)
The reaction of FA-CoA with glycerol 3-phosphate takes 
place in two steps (Figure 1.7). The first step, catalysed 
by GPAT, involves esterification of a long chain fatty acyl 
CoA group into position 1 of glycerol 3-phosphate to form 
1-acyl glycerol 3-phosphate (lysophosphatidate). The 2nd
Figure 1.6
Long chain fatty acid esterification (glycerolipid biosynthesis)
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Legend to Figure 1.6
1. Fatty acid CoA ligase
2. Glycerol 3-phosphate acyl transferase
3. Dihydroxyacetone-P-acyltransferase
4. Acyl(alkyl)dihydroxyacetone-P-oxidoreductase
5. Lysophosphatidic acid acyltransferase
6. Phosphatidic acid phosphatase
7. Diacylglycerol kinase
8. Diacylglycerol acyltransferase
9. Choline kinase
10. Choline-P-cytidyltransferase
11. Diacylglycerol cholinephosphotransferase
12. Ethanolamine kinase
13. Ethanolamine-P-cytidyltransferase
14. Diacylglycerolethanolaminephosphotransferase
Figure 1.7 
Fatty acid esterification
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step involves esterification at the 2-position to form 
diacylglycerol 3-phosphate (phosphatidate). Both activities 
may reside in the same enzyme (Bell and Coleman, 1983).
GPAT activity has been found in both mitochondrial and 
microsomal fractions in rat heart, liver and adipose tissue 
(Daae and Bremer, 1970); the two subcellular locations 
contain different isoenzymes with different properties 
(Nimmo, 1979). In adipose tissue less than 10% of total 
GPAT activity is present in the mitochondrial fraction, but 
in liver and heart the activities are distributed approximately 
equally (Bremer et al., 1976). Most work outside this 
laboratory has focussed on the enzyme from adipose tissue: 
microsomal GPAT activity is inhibited by sulphydryl reagents 
such as N-ethyl maleimide whilst the mitochondrial activity is 
unaffected; this property can be used to distinguish between 
the two isoenzymes (Saggerson et al., 1979). The two 
isoenzymes also differ in their pH optima and Km's for 
palmitoyl CoA. The principle site of glycerolipid synthesis 
is the endoplasmic reticulum where GPAT activity is not 
specific, using palmitoyl CoA and oleyl CoA with equal 
efficiency (Haider, 1978). In contrast, the mitochondrial 
enzyme has a lower Km for palmitoyl CoA (Monroy et al.1973) 
and may be important for precise specificity during 
esterification.
16
d) Oxidation of fatty acyl CoA 
Cytosolic fatty acyl CoA thioesters can either be 
esterified to form glycerolipids, as has been described, or 
oxidized within the mitochondrion (McGarry and Foster, 1980).
In liver, the activity of the 1st enzyme in each pathway has 
a reciprocal relationship (Borrebaeks et al., 1974); during 
starvation, for example, the activity of GPAT fell and that 
of carnitine acyltransferase^ (CAT^ .) rose, the reverse 
occurring on refeeding. However, in heart the activities 
of GPAT and CAT^ were found not to alter with the nutritional 
state of the animal (Borrebaeks et al., 1974).
Carnitine Acyltransferase (CAT) (EC 2.3.1.21).
CAT catalyses the transfer of fatty acyl CoA esters 
from the cytosol into the mitochondria (Figure 1.8). It 
exists in two forms located on the outside (CAT^) and inside 
(CAT^j) of the inner mitochondrial membrane (Bremmer, 1977).
CAT^ catalyses the formation of acylcarnitine from acyl CoA
and carnitine; acyl carnitine is then transferred to the inside
of the inner mitochondrial membrane where C A T ^  catalyses
the reverse reaction to release acyl CoA into the mitochondrial
matrix.
Malonyl CoA (an intermediate in fatty acid synthesis) 
is a potent inhibitor of CAT"'- (but not CAT^) in rat liver 
and heart (McGarry et al., 1978a,b,c; Saggerson, 1982).
The mechanism of inhibition is not known, but may involve a
17
Figure 1.8
Transfer of fatty acyl CoA across the inner mitochondrial 
membrane
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competitive inhibition against acyl-CoA substrates. The 
concentration of malonyl CoA in both liver and heart 
fluctuates with the nutritional status of the animal 
(McGarry et al., 1977, 1983). Thus during starvation, 
fatty acid synthesis and malonyl CoA concentration are low 
whilst CAT^ activity and fatty acid oxidation are elevated 
(McGarry and Foster, 19 80). These changes appear to be 
mediated by the glucagon/insulin ratio (McGarry et al 1978b): 
glucagon inhibits fatty acid synthesis and thus decreases 
malonyl CoA concentration whereas insulin stimulates fatty 
acid synthesis. During starvation glucagon levels are high 
and CAT^ activity is stimulated, on refeeding, glucagon 
levels fall and insulin levels rise causing inhibition of 
CAT^ (McGarry and Foster, 1980).
1.2 Catecholamines and the heart
Adrenaline and noradrenaline are naturally occurring 
catecholamines which mediate a variety of cellular functions. 
These hormones are released in response to stress and cause 
changes in both the physiology and biochemistry of the 
animal.
In heart, noradrenaline (released on stimulation of 
sympathetic nerves) and circulating adrenaline (produced 
by the adrenal gland) cause an increase in cardiac output.
This involves an increase in both heart rate (chronotropy) 
and force of contraction (inotropy). To meet the increased 
energy demands, catecholamines also increase energy production
19
by myocardial metabolism. These hormones act on a- and 
3~adrenergic receptors at the cell membrane to generate 
intracellular 2nd messengers which mediate the cellular 
response of the hormone.
a) g-adrenergic receptors
Stimulation of 3-receptors generates cyclic AMP (cAMP) 
(review Hayes, 1986). The pathway of cAMP formation is 
well established and is outlined in Figure 1.9. cAMP 
mediates a variety of cell responses by activating cAMP- 
dependent protein kinase (cAMP-PrK) which in turn 
phosphorylates and thereby changes the activity of numerous 
enzymes, including those involved in both muscle contraction 
and energy metabolism. A more detailed description of the 
effects produced by cAMP-PrK, relating to the work of this 
thesis, is given in subsequent sections.
b) a-adrenergic receptors
a-adrenergic receptors have been divided into two 
subtypes “ an<^  a^* Stimulation of ex2 receptors has 
essentially the opposite effect of that of 3-receptors; 
deactivation of adenylate cyclase producing a reduction in 
cAMP levels (Jakobs et al., 1981).
More recently it has been established that activation
of a^-receptors produces two 2nd messengers - inositol 1,4,5-
triphosphate (IP_) and diacylglycerol (DAG) (review, Berridge
2+19 87). IP^ produces an increase in [Ca and DAG activates
protein kinase C (PKC).
20
Figure 1.9
B-Adrenergic receptor coupling to adenylate cyclase
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i) g^-regulation of Ca release
The pathway of g^-induced formation of 2nd messengers
is shown in figure 1.10. Binding of agonist to the
receptor triggers GTP-dependent activation of phospholipase
C which hydrolyses membrane phosphoinositides - hydrolysis
of phosphoinositoldiphosphate (PIP2) results in formation
of IP^ and DAG. IP^ binds to a site on the endoplasmic
2+reticulum to induce release of Ca (Figure 1.11). IP^ 
may then be used to re-form phosphoinositides or further 
metabolized to has been implicated in a sustained
24-
entry of Ca from outside the cell. IP^ can be further
phosphorylated, but the role of these isomers is not yet
known. When the agonist is removed, IP^ and IP^ levels decline
2+rapidly thus reducing [Ca ]^. (review Berridge, 1987).
g^-induced stimulation of phosphoinositide turnover was 
first shown to occur in heart muscle by Brown et al. (1985).
ii) g^-induced activation of protein kinase C (PKC)
g^-activation induces DAG formation which then activates
PKC (Figure 1.11) following stimulation of cells, PKC is
translocated from the cytosol to the membrane. Phospholipid
2 +(particularly phosphatidylserine - PS) and Ca , as well as 
DAG, are reguired for optimal activation of PKC (review 
Nishizuka, 1986). PKC has been purified from heart (Kuo 
et al., 1984) and several in vitro substrate proteins
Figure 1.10
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Legend to Figure 1.10
Ptd Ins - phosphatidy1 inosito1 
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Gp - guanine nucleotide binding protein
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Dual signal response to phosphatidyl inositol turnover
(from Berridge, 1987)
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identified (Iwasa and Hosey, 1984; Yuan and Sen, 1986) 
e.g. troponin-I, troponin-T and phospholamban 
(Movesesian et al., 1984).
iii) Phorbol esters
Phorbol esters have a structure very similar to that 
of DAG and can activate PKC directly in vivo and iji vitro 
(Castagna et al., 1982). The main difference between 
phorbol esters and DAG is that DAG is present only transiently 
following a^-stimulation, but phorbol esters are not 
degraded by cells. Therefore, phorbol esters may prolong 
the response and give a distorted picture of the normal 
sequence of events.
Phorbol esters have been found to decrease contractility 
in cultured chick heart cells (Leatherman et al., 1987) and 
isolated perfused rat heart (Yuan et al., 1987). However, 
exactly how PKC activation exerts these inhibitory effects 
is not known.
2+1.3 Factors controlling the level of Ca in the cytoplasm
The calcium concentration of the myoplasm determines
the activation of contractile and other proteins. The
2+intracellular free calcium concentration ([Ca ]^) in
quiescent cardiac muscle is 0.1 - 0.3yM (Marban et al.,
2+ 2+1980). Since [Ca ] is 1 - 2mM, the Ca level of the
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cytoplasm must be controlled tightly to prevent a
2+continuous entry of Ca into the cell (review: Hiraoki
and Vogel, 1987).
a) The cardiac action potential
Under normal conditions the heart contracts at a constant
rate. Electrical impulses originate in the sinoatrial node
and are conducted throughout the muscle cells in a coordinated
manner to allow synchronised contraction (review, Kass and
Scheuer, 19 82). On reaching the cell, the impulse causes
depolarization by opening voltage-dependent Na+ channels in
the sarcolemma. Na+ ions flood into the cell to produce
the inward Na+ current (INa) which is quickly inactivated
by opening of K+ channels which allow outward K+ movement
(IK). The cardiac action potential differs from that of
skeletal (and smooth ) muscle in that it also contains a 
2+slow inward Ca current (ICa) which causes a prolonged 
action potential (Bowman et al., 1985):
0
mV
INa
ICa
K
-80
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The activation of contractile proteins is initiated 
2+
by Ca release from the sarcoplasmic reticulum, however,
exactly how the action potential at the sarcolemma induces
2+ 2+ such Ca release is poorly understood. A 'Ca -induced
2+
Ca release' has been proposed (Fabioto and Fabioto, 1977)
2+whereby entry of a small amount of Ca during the action
2 +potential triggers opening of a Ca channel in the 
sarcoplasmic reticulum, hut other mechanisms may also 
operate (review, Hiraoki and Vogel, 1987).
It is not necessary to give a description of muscle 
contraction in this thesis, but a review can be found in 
Katz (1984) and England (1983).
b) Ca^+ entry (Figure 1.12)
2+Increases in ICa due to stimulation of a^-receptors
have been described in Section 1. 3-receptor stimulation
2+ 2+ can also induce Ca entry via Ca 'slow' channels (Reuter,
1974). Catecholamines increase the probability of the
channel being in the open configuration; this is probably
due to phosphorylation by cAMP-PrK of a membrane protein-
calciductin -which resembles phospholamban (Rinaldi et al. ,
1981) since phosphorylation of calciductin induced by
2+catecholamines parallels the stimulation of Ca slow 
channel activity (review, Carafoli, 1984).
2+Ca uptake from the sarcoplasmic reticulum is 
regulated by phospholamban (review Katz, 1984), a membrane
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Figure 1.12 
Mechanisms regulating internal [Ca2+1
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protein which can be phosphorylated by both cAMP-PrK and 
calmodulin-dependent protein kinase.
2+c) Ca removal (Figure 1.12)
2+ 2+As [Ca approaches lyM, Ca -ATPases of the
sarcoplasmic reticulum and plasma membrane are activated .
2+Ca is thus actively removed from the cell allowing
+  21-relaxation (Rasmussen, 1983). There is also an Na -Ca
exchanger in the plasma membrane which normally acts to
2+ + remove 1 Ca ion by allowing entry of 3 Na ions (review,
Inesi, 1985). Since the Na+ gradient across the cell is
established by the Na+-K+ ATPase (which actively pumps
3 Na+ out of the cell whilst allowing entry of 2 K+), the
Na+-Ca^+ exchange will also be influenced by ATP. If
2+ 2+[Ca ] rises above lyM, the excess Ca is absorbed by
mitochondria together with Pi resulting in calcium phosphate
21-precipitation. When [Ca falls, mitochondria release
2+ + 2+Ca through a Na -Ca exchanger.
Although the functions of these membrane transport 
proteins are understood, details of their structure are 
only now emerging.
1.4 Adrenergic control of metabolism
Stimulation of the heart with catecholamines stimulates 
both glycogen and lipid metabolism. How catecholamines 
alter the activity of key enzymes in these pathways is 
described in the following sections.
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a) Glycogen metabolism
Catecholamines stimulate glycogenolysis whilst 
inhibiting glycogen synthesis (review, Hayes 1986). This
is summarized in Figure 1.13. Glycogen phosphorylase 
catalyses the initial, rate limiting step of glycogen 
degradation.
(a 1,4-glucoside)n + Pi ---^ (a 1,4 - g l u c o s i d e ) +
glucose 1- P
Phosphorylase exists in two forms - a phosphorylated ('a') 
form and dephosphorylated ('b') form. Phosphorylase *b' 
is only active upon binding of 5^-AMP, an allosteric 
activator (Fletterick and Madsen, 19 80). Phosphorylase 
'a* is also activated by AMP, but at saturating substrate 
concentrations is independent of the nucleotide. 
Phosphorylase can be inhibited by glucose, glucose-6- P 
and ATP.
Conversion of phosphorylase 1 b' to the active 'a' form
is catalysed by phosphorylase kinase (PhK). PhK contains 
2+Ca -binding subunits which are identical to calmodulin and
2+is thus activated by binding Ca . PhK is also regulated
by phosphorylation. Phosphorylation by cAMP-PrK activates
2+the enzyme and also increases its sensitivity to Ca
2+Dephosphorylated PhK has no activity in the absence of Ca
(review, Hayes, 1986). Thus 8-agonists stimulate
phosphorylase by activating PhK by both cAMP-dependent
2+phosphorylation and an increase in [Ca ]^.
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Figure 1.13
Regulation of glycogen metabolism
(from Hayes, 1986)
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2+
a^-agonists also stimulate Ca entry into the cell 
and thus activate PhK. Whether the second branch of the a^- 
signalling patnway, i.e. PKC activation, is involved in 
activating phosphorylase will be discussed in the 'Discussion'.
Dephosphorylation and thus inactivation of phosphorylase 
is catalysed by protein phosphatases (review, Cohen, 19 88).
The activity of phosphorylase phosphatase is regulated by a 
protein termed inhibitor-1. Inhibitor-1 is phosphorylated 
and activated by cAMP-PrK to inhibit the phosphatase and 
thereby activate phosphorylase.
At the same time as phosphorylase is activated, the
activity of glycogen synthase (GS) is inhibited by
phosphorylation. GS contains at least 7 phosphorylation
sites (Cohen, 19 83) and can be phosphorylated by cAMP-PrK,
2+Ca calmodulin-dependent PrKs (including PhK) and possibly 
PKC (GS is a substrate for PKC in vitro - Nishizuka, 1986).
b) Regulation of lipolysis
Release of fatty acids from endogenous triglyceride is 
under acute hormonal control in heart (Severson, 19 79): 
perfusing the isolated rat heart with catecholamines causes 
a decrease in triglyceride levels (Crass et al., 1975).
The effect seems confined to 8-receptors since stimulation 
of a^-receptors has no measurable effect on lipolysis 
(Fain and Garcia-Sainz, 1983).
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The rate-limiting step in triglyceride hydrolysis is 
catalysed by triglyceride lipase (TGL). In adipose tissue, 
TGL (also called 'hormone-sensitive lipase') is phosphorylated 
and activated by cAMP-PrK upon ^-stimulation (Belfrage et al.,
1980). However, the regulation of myocardial TGL is more 
controversial. Goldberg and Khoo (19 85) and Heathers et al. 
(1985) found a cAMP-dependent stimulation of TGL activity 
in vitro. Also, Palmer et al. (1987) found that stimulation 
of the lipase was blocked by using a protein kinase inhibitor. 
However, Schoonderwoerd et al. (19 87) suggested that cAMP- 
induced stimulation of TGL was by an indirect mechanism 
rather than a direct phosphorylation (this is discussed in 
more detail in 'Discussion'). However, most recent evidence 
appears in favour of a cAMP-dependent phosphorylation of TGL 
(Holm et al., 1988; Small et al., 1989).
Again, stimulation of TGL is confined to 8-receptors 
since perfusion of hearts with a^-agonists has no effect 
on TGL activity (Heathers et al., 1985).
As well as being under hormonal control, TGL is 
inhibited by fatty acids and fatty acyl CoA compounds 
(Severson and Hurley, 1982).
c) Control of esterification
GPAT controls the first, rate limiting step in 
esterification of fatty acids to triglycerides (Bell and 
Coleman, 1983) . GPAT has been studied mainly in adipose 
tissue, the only published work on control of the myocardial
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enzyme coming from this laboratory.
Rider and Saggerson (19 83) observed a reduction in
GPAT activity on incubation of rat adipocytes with
noradrenaline; in whole homogenate, both mitochondrial and
microsomal activities were depressed, but after isolation
of the fractions, the effect persisted in the microsomal
activity also. However, they found that including albumin
in the homogenisation buffer removed the effect of
noradrenaline, and incubation with cAMP-PrK had no effect
on GPAT activity. In contrast to these results, Niramo and
Houston (19 78) described an inhibition of adipose tissue
GPAT with cAMP-PrK. This was initially thought to be due
to phosphorylation of GPAT (Nimmo, 19 81) since labelling
of a band (upon SDS-PAGE of adipocyte microsomes) of
Mr 54000, thought to be GPAT, occurred on incubation with
32cAMP-PrK and (y P)ATP. However, later work (Nimmo and 
Nimmo, 19 84) concluded that the labelled band differed by 
500-1000 in Mr from that thought to be GPAT. The mechanism 
of catecholamine-induced inhibition of GPAT in adipose tissue 
therefore remains unsolved; it is unlikely to be due to an 
increase in the concentration of free fatty acids since 
these do not inhibit GPAT in vitro (Rider and Saggerson, 1983).
Perfusion of hearts with either or B-agonists 
causes a decrease in GPAT activity in whole homogenates 
(Heathers et al., 1985); this inhibition can be reversed 
upon incubation of heart extracts under conditions favouring 
activation of protein phosphatases. Also, incubation of 
homogenates with cAMP-PrK inhibits GPAT activity. Thus
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evidence so far from heart favours a phosphorylation of 
GPAT by cAMP-PrK in response to ^-stimulation of the heart.
The mechanism of the a^-induced inactivation of GPAT is not 
known and has been the subject of work carried out in this 
thesis.
1.5 Ischaemia
Ischaemia is defined as decreased blood flow through 
a tissue. Two types of ischaemia exist: chronic and
acute. In man the most common cause of chronic ischaemia 
is atherosclerosis, a process which involves narrowing of a 
coronary artery by deposition of lipid and fibrous material 
along the lining of the artery. Flow changes resulting from 
such plaque formation increase the risk of both endothelial 
damage and platelet aggregation and thrombus formation (Azuma 
and Fukushima, 19 76.)
Acute ischaemia is caused either by coronary thrombosis 
(blockage of a vessel by a fragment of solid material, usually 
sloughed off from atheromatous accumulations) or sudden 
occlusion of a coronary vessel due to a spasm of the artery.
In 1912 a connection was established between coronary artery 
obstruction, anginal pain and sudden death (Herrick, 1912). 
The majority of thrombi occur in the left anterior descending, 
right and circumflex coronary arteries (Silver et al., 1980).
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Chronic ischaemia is difficult to study experimentally 
due to the time required to establish the condition and 
nature of the causative factors. However, several methods 
can be used to study acute ischaemia; occlusion in situ 
of coronary vessels in dog hearts (Braunwald et al., 1974), 
occlusion of coronary vessels in the isolated perfused rat 
heart (Kannengeiser et al., 1975) or reduction in flow to 
the whole heart (global ischaemia).
a) Arrhythmias - general
The majority of people who die during a heart attack 
do so soon after the onset of symptoms (Riemersma, 1987). 
Abnormalities of the heartbeat, which occur during ischaemia 
or subsequent reperfusion account for at least half the 
deaths due to acute myocardial infarction (Armstrong 
et al., 1972). Early arrhythmias occur within minutes of 
occlusion (Kaplinsky et al., 1979) and are the major cause 
of sudden death; late arrhythmias may appear days or weeks 
after the infarction and can usually be controlled by drugs.
The mechanisms involved in the genesis of early 
arrhythmias differ from those of late arrhythmias. Early 
arrhythmias may be due to metabolic and ionic disturbances 
occurring immediately after the onset of ischaemia (Corr 
and Sobel, 1979); this is discussed below.
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b ) Carbohydrate utilization and energy status
Ischaemia results in a reduced delivery of substrates 
and oxygen to the cell which causes a shift from aerobic 
fatty acid oxidation to anaerobic glycolysis (glycogenolysis 
is stimulated to provide glucose). The falling ATP levels 
produce an increase in the concentrations of ADP, AMP and Pi; 
this activates phosphofructokinase and hence increases 
glycolytic flux (Newsholme, 1972). Oxygen deficiency 
also increases the NADH/NAD+ ratio causing inhibition of 
pyruvate dehydrogenase and glyceraldehyde 3-phosphate 
dehydrogenase (Neely and Morgan, 1974).
However, as lactate (the major end product of 
anaerobic glycolysis) accumulates, both glycolysis and 
glycogenolysis are inhibited (Rovetto et al., 1975); 
lactate also causes a drop in intracellular pH which 
contributes to the inhibition of glycolysis (Neely and 
Morgan, 1974).
Thus very little glycolytic ATP can be produced during 
ischaemia and the level of phosphocreatine falls in an 
attempt to maintain ATP levels (Garlick et al., 1979). After 
approximately 15 mins. ischaemia, ATP levels have fallen by 
over 70% (Jennings et al., 19 85) and the adenine nucleotide 
pool (ADP, AMP) is rapidly degraded to inosine and then to 
hypoxanthine and xanthine.
38
c) Ionic changes
The membrane channels controlling the fluxes of Na+ ,
+ 2~h
K and Ca in non-ischaemic myocardial cells have been
described (Section 1.3). Efflux of K+ via the Na+ K+
ATPase is normally inhibited by ATP but during ischaemia when
ATP levels fall, the channel is activated (Noma, 1983). This, 
• "t* 2 *1“m  turn, disrupts Na -Ca exchange which, together with the
2+reduced activity of the Ca -ATPase (which normally actively
2+ + pumps Ca out of the cell) results in an increase in [Na ].
2+and an increase in tea ]^. The consequences of the increase 
2 +in Ca level are described in Section 1.6.
d) Catecholamines and the ischaemic heart
i) Catecholamine release
Increased adrenergic activity occurs in the acutely 
ischaemic myocardium (Carlsson et al., 1985) which may be 
due to activation of sympathetic nerves (Karlsberg et al., 
1979) or local cardiac reflexes (Bosnjak et al., 1979).
Also, direct effects on adrenergic neurones, independent of 
nerve impulses, could induce noradrenaline release or inhibit 
reuptake mechanisms. For example, an increase in extra­
cellular K+ concentration can induce noradrenaline release 
(Lorenz and Vanhoutte, 1975) . Also an increase in blood 
catecholamine levels can accompany ischaemia (Ceremuzynski,
1981).
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ii) Arrhythmias
The increased adrenergic activity in the ischaemic 
tissue stimulates 3-receptors and intracellular cAMP levels 
rise markedly during ischaemia (Krause and Wollenberger,
1967; Opie et al., 1979). However, no clear cut relationship 
between cAMP levels and the development of arrhythmias can be 
demonstrated (Kane et al., 1985).
However, there is a large body of evidence implicating 
noradrenaline in the development of ischaemia-induced 
arrhythmias: (i) Chemical denervation by 6-hydroxydopamine
abolishes ventricular fibrillation during both occlusion and 
reperfusion in cat heart (Sheridan et al., 1980) (ii)8 - 
adrenergic antagonists decrease the incidence of ischaemia- 
induced arrhythmias (Khan et al., 1972) e.g. pre-perfusion 
with 8-antagonists reduced the incidence of ischaemia- 
induced arrhythmias in isolated rat hearts (Kane et al., 1979; 
Campell et al., 1981) (iii) Sheridan et al. (1980) found 
that a^-blockade with phentolamine reduced the incidence of 
both ischaemia and reperfusion-induced arrhythmias in cat, 
suggesting that events triggered by a^-stimulation also 
contribute to arrhythmogenesis.
e) Lipid metabolism
During ischaemia, fatty acids and their metabolites 
accumulate due to an inhibition of fatty acid oxidation and 
lack of removal of metabolites normally washed away in the 
blood. Accumulation of such metabolites may contribute to 
cell damage and myocardial dysfunction occurring during
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ischaemia.
i) Triglycerides
Glycerol is released in considerable amounts from 
ischaemic tissue (Vik-Mo et al., 1979) suggesting increased 
triglyceride hydrolysis. This is supported by the finding 
of an elevated TGL activity in ischaemic rat heart (Heathers 
and Brunt , 1985). However, a decreased content of 
triglyceride in ischaemic hearts could not be demonstrated 
(van Bilsen et al., 1989). It has been suggested that 
increased cycling of triglycerides occurs during ischaemia 
(Stam et al., 1987); the build up of glycolytic intermediates 
(such as glycerol 3-phosphate) stimulating re-esterification 
of fatty acids. However, this requires energy (ATP) to 
activate fatty acids to fatty acyl CoA, and it seems unlikely 
that the myocardium could spare ATP in this way. Also,
Heathers and Brunt (19 85) found a decreased GPAT activity in
ischaemic myocardium which would inhibit re-esterification.
It is possible that small changes in triglyceride levels 
(which would be enough to produce a measurable increase in 
fatty acid levels) are missed by current assay procedures, 
as suggested by van Bilsen et al., (1989).
The stimulation of TGL and inhibition of GPAT during 
ischaemia appears to be mediated by $-adrenergic receptors: 
Heathers and Brunt (19 85) found that preperfusion of the
isolated rat heart with 8-, but not a^-adrenergic antagonists
prevented the ischaemia induced changes in enzyme activity.
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ii) Phospholipids
Phospholipids are another possible source of the 
increased fatty acids in ischaemic tissue.
However, there are conflicting reports on phospholipase 
activity in ischaemic hyocardium: Internal calcium increases
during ischaemia and has been suggested to activate PLA^
(Saxon et al., 1984) but Bentham et al., (1987) found a 
reduced PLA^ activity in ischaemic heart and suggested that 
inhibition by lysophosphoglycerides and acylcarnitines 
occurred. However, a decrease in phospholipid synthesis
may occur, and a decreased lysophosphatidylcholine 
acyltransferase activity has been reported in pig heart, 
and also a decreased acyl CoA synthetase (Das et al., 1986).
As with triglycerides, no change in the phospholipid 
content of ischaemic myocardium can be detected (van der Vusse 
et al., 1987). Since levels of fatty acids (van Bilsen et al., 
1987) acyl-CoA acyl carnitine (Neely et al., 1979; Shug 
et al., 1978) “and lysophosphatidylcholine (Corr et al.,
1983) have all been shown to increase, it is obvious that 
lipid metabolism in ischaemic tissue is impaired, but the 
mechanisms responsible have yet to be determined.
iii) Toxic effects of lipid metabolites
Normally, long chain acyl carnitines (LCAC) are 
concentrated in internal membranes with very little in 
sarcolemma (Knabb et al., 1985). However, hypoxia leads
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to a 5-fold increase in the total [LCAC] but a 70-fold 
increase in the sarcolemma (Knabb et al., 1986).
Pretreatment of hypoxic myocytes with 2-[5-(4-chlorophenyl) 
pentyl]oxirane-2-carboxylate (POCA - a specific inhibitor 
of carnitine acyltransferase I) abolished the electro- 
physiological derangements associated with hypoxia and also 
the increase in a^-receptor density that occurs in hypoxic 
myocytes (Heathers et al., 1986). Analogous changes occur 
in ischaemic hearts in vivo in response to POCA (Creer et al., 
1987) .
A translocation of 8-receptors from an intracellular 
light vesicle fraction to the sarcolemma of guinea pig hearts 
has been demonstrated (Maisel et al., 1985), but a similar 
translocation does not occur for a^-receptors. Therefore, 
the increase in a^-density seen during hypoxia and ischaemia 
may be due to exposure of latent a^-receptors in the 
sarcolemma, possibly by insertion of LCAC into the membrane 
(Heathers et al., 1986).
The electrophysiological alterations contributing to 
arrhythmogenesis in the ischaemic heart occur within 
minutes. Therefore, implication of specific metabolites 
requires accumulation within a correspondingly brief time 
interval. (< 15 min.) (Corr et al., 1987). Lysophospholipids 
(LPLs) accumulate rapidly in ischaemic myocardium (Corr et al., 
1986). The overall concentration of lysophosphatidylcholine 
(LPC) in ischaemic heart is -1.2mM. Exposure of tissue to
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1.2mM LPC + 0.4mM albumin leads to electrophysiological 
alterations (Corr et al., 1979); in absence of albumin, 
10-75yM is effective (Corr et al., 1981). Man and
2+Lederman (1985) found that lowering the perfusate [Ca ]
had a beneficial effect on LPC-induced arrhythmias in isolated
24-rat heart, but the role of Ca in the LPC-induced 
arrhythmias is not known. LPC also has a positive inotropic 
effect which may reflect a stimulation of adenylate cyclase 
(Sedlis et al., 1983).
LPLs are amphipillic.molecules, by inserting into the 
lipid bilayer they can alter the physical and electrical 
properties of biological membranes (Fink and Gross 1984).
Thus LPL-induced changes may contribute to the changes seen 
in ion conductances during ischaemia.
1.6 Reperfusion
The heart cannot recover from an ischaemic episode 
without restored coronary flow, but reperfusion itself may 
cause further damage (Corr and Witkowski, 1984; Manning 
and Hearse, 1984).
Periods of ischaemia greater than approximately 30 min. 
cause irreversible cell injury (review, Hess and Manson,
1984) . Earlier reperfusion salvages the myocardium but 
severe mechanical dysfunction may persist. This delayed 
recovery has been termed 'stunning' (Ellis et al., 1983):
ATP levels may remain depressed (De Boer et al., 1980) and
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fatty acid levels remain elevated (van Bilsen et al., 1989; 
Hara et al., 1989).
a) Adrenergic activity and arrhythmias
Reperfusion of an ischaemic area can induce arrhythmias 
which occur within the first minute of reperfusion; the 
incidence of arrhythmias depends on the duration of the 
preceeding ischaemic episode, being maximal after 15 min. 
ischaeimia in rat hearts (Mannings, 19 86). Adrenergic 
antagonists have been shown to be beneficial in protecting 
against reperfusion-induced arrhythmias (Jennings, 1985 - 
review).
There is evidence for an increase in a adrenergic 
activity on reperfusion of a previously ischaemic area; 
Sheridan et al., (1980) found that both a and 8-blockade 
decreased the incidence of ischaemia-induced arrhythmias, 
but only a-antagonists reduced the incidence of arrhythmias 
during reperfusion (using anaesthetized cat model). An 
increased a-adrenergic activity has also been reported by 
Stewart et al.(1980) and Sharma et al., (1983).
On reperfusion of the isolated rat heart, TGL activity 
returns to pre-ischaemic values but GPAT activity is further 
reduced (Heathers and Brunt, 1985). Preperfusion with 
the a^-antagonist doxazosin, but not the $-antagonist 
atenolol, prevented the reperfusion-induced fall in GPAT 
activity. Also perfusion of normal hearts with the a^-
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agonist methoxamine inhibited GPAT with no change in TGL 
activity. Therefore, it appears that a^-receptor mechanisms 
are responsible for the reperfusion-induced fall in GPAT 
activity.
b) Free radicals
Reperfusion also causes formation of oxygen-derived 
free radicals (McCord, 1985). Under normal conditions, 
free radical scavengers (catalase and superoxide dismutase) 
can pick up the free radicals and prevent cell damage. 
However, during ischaemia there is a decrease in the number 
of scavengers which are therefore unable to metabolize the 
radicals formed on reperfusion. Free radicals damage cells 
mainly by lipid peroxidation; unsaturated fatty acids and 
membrane phospholipids react to give an alkyl radical 
followed by a lipid-peroxy radical. This causes dis­
organization of membrane structure and function (Noronha- 
Dutra and Steen, 1982). This injury can be potentiated 
by amphiphiles (Mak et al., 1986) i.e. production of 
lysophospholipids and LCACs during ischaemia may enhance 
reperfusion injury due to peroxidation of the sarcolemma.
2+c) Ca in ischaemia and reperfusion
Shen and Jennings (1972) were the first to report an 
2+increase in [Ca ] during ischaemia and reperfusion of the 
canine myocardium which was associated with cell damage.
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2 +A summary of the consequences of altered Ca homeostatis
2+is given in Figure 1.14. This link between Ca overload
and irreversible cell injury also occurs in certain
2 +cardiomyopathies, the Ca paradox and hypoxia (review,
2+Nayler et al., 19 85). An increased Ca entry on
reperfusion occurs even after relatively short periods of
ischaemia and this increase could be blocked by the a^-
antagonist prazosin (Nayler et al., 1985), suggesting that 
2 +initial Ca uptake on reperfusion is mediated by a^- 
receptors.
2+Following a period of Ca -free perfusion ( 2 - 3  min.)
2 +in rat myocardium, perfusion with Ca causes extensive cell
2+damage. This is known as the 'Ca paradox' (Zimmeman 
and Hulsmann, 19 66) and the resultant cell damage is similar 
to that occurring on reperfusion of ischaemic myocardium 
(review, Hess and Manson, 1984).
2+The mechanism of the increased [Ca ] during ischaemia
and reperfusion is complex (review, Jennings et al. , 1985)
2+(i) local release of catecholamines may stimulate Ca entry
via the slow channels (ii) reduced ATP levels inhibit active 
2+Ca efflux (iii) free radicals may disrupt membrane
2+structure and increase the permeability to Ca (Murphy et al., 
2+1986) (iv) Ca accumulation may be augmented by an increased
a^-adrenergic activity (review, Corr and Sharma, 1984)
(v) palmitoyl carnitine accumulates during ischaemia and
2+this can activate voltage-dependent (slow) Ca channels
Figure 1.14
Consequences of altered Ca2+ homeostasis
(from Murphy et al., 1987)
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(Mir and Spedding, 19 86) at a concentration similar to 
that found in ischaemia (Spedding, 1987).
Thus attempts to preserve myocardial function during
ischaemia and reperfusion by inhibiting a single pathway 
2+of Ca influx is likely to be met with only limited success.
2+
i) Ca channel antagonists and arrhythmias
Fleckenstein and colleagues in the 1950s first 
established the therapeutic ability of calcium antagonism, 
(review: Flickenstein, 1984) and the organic calcium 
antagonists are now used widely in the treatment of coronary 
artery disease: Roberts et al., (1986) demonstrated that
a daily dose of diltiazem prevented the development of 
reinfarction in patients who had suffered an infarction.
2+Ca antagonists
2+The organic Ca channel antagonists have been divided 
into three subtypes based on pharmacological and structural 
data (review, Schwartz, 1987): (i) 1,4-dihydropyridines
(nifedipine, BayK8644) (ii) phenylalkylamines (verapamil) 
and (iii) benzothiazipines (diltiazem). Model building 
from the chemical structures (Figure 1.15) revealed completely 
different shapes, suggesting either multiple receptor types 
or multiple sites on a single receptor. The slow channel 
has two major subunits of Mr 170 000 each (a^ and c^)•
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Figure 1.15 
Structures of three Ca^+ antagonists
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However, only the a-^-subunit has binding sites for the 
2 +Ca blockers (Lazdunski, 1988).
2+The Ca antagonists may possess properties other than
2+Ca antagonism, especially at higher concentrations
_6 +
(>10 M): diltiazem and verapamil can inhibit Na channels
(Bayer et al., 1975), verapamil may also have intracellular
sites of action (Kaufmann, 1977) and interaction with a^-
receptors has also been reported, being most marked for
verapamil and least for nifedipine (Corr and Sharma, 1984;
Nayler et al., 1982). The antagonists also produce
vasodilation and negative inotropy and chronotropy (Schwartz
and Triggle, 1984; Braunwald, 1982).
Arrhythirtlas
Reperfusion-induced arrhythmias (RIAs) have been widely
observed both _in vivo (Crome et al. , 1986; Sheridan et al.,
1980) and in vitro (Lubbe et al., 1983; Manning and Hearse 
2+1984). Ca antagonists protect against ischaemia-induced 
arrhythmias (IIAs) but their ability to combat RIAs is 
controversial e.g. reports of verapamil being protective 
(Natto et al., 1981) and ineffective (Ribeiro et al., 1981) 
in dogs.
Interpretation is complicated when different experimental
conditions are used e.g. drug dosage and administration, and
2 +also because many Ca channel antagonists have other 
pharmacological properties. There is also conflicting 
evidence about diltiazem, whose properties are relatively
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specific: ineffective against RIAs in dogs (Sheehan et al.,
1982) but effective in rat (Kinoshita et al., 1987) and 
cat (Schwartz et al., 1986).
Tosaki et al., (1987) using isolated rat hearts, found
that diltiazem reduced the rate of ventricular reperfusion
induced fibrillation (VF) when given prior to occlusion, but
not if administered just prior to reperfusion. This suggests
that the activity of the slow channel during the early
moments of reperfusion may be discounted as a determinant of
the vulnerability of the heart to arrhythmias. This supports
the conclusion of Marshall et al. (1981) and Manning et al .
2 +(1985) that slow Ca antagonism per se does not directly 
influence the incidence of RIAs.
Tosaki et al«(1987) also found that the anti-arrhythmic
properties of diltiazen were secondary to its ability to
reduce heart rate since, if the decrease is prevented by
pacing, the anti-arrhythmic properties are lost. This
2+beneficial action of Ca antagonists in reducing hoth 
inotropy and chronotropy has been frequently proposed 
(Csik et al., 1983). Bolli et al. (1986) reported a 
positive correlation between heart rate and the incidence 
of IIAs in dogs.
1.7 Diabetic myocardium ■
Cardiac disease is the main cause of mortality in 
human maturity - onset diabetes mellitis (Bradley, 1971). 
Although atherosclerosis of coronary arteries is a major 
problem (Ostrander and Epstein, 1976) there is also evidence
for a primary cardiomyopathy (congestive heart failure) 
in humans which cannot be explained by hypertension or 
valvular disease (Shapiro, 1982; Regan et al., 1977): 
reduced contractility (Feen et al., 1980); accumulation 
of periodic-acid Schiff (PAS) material in chronically 
diabetic dogs (+ collagen) causes increased 'stiffness' 
of the myocardium (Regan et al., 1974); electrophysiological 
abnormalities (Senges et al., 1980); ultrastructural 
alterations (Trach, 1976); defects in the activities of various 
organelles (Penparghul et al., 1981) (all observed in 
hearts from chemically-induced diabetic animals). A number 
of metabolic changes occur in diabetes and these are 
summarized in Figure 1.-16.
a) Animal models of diabetes
The most commonly used models for studying diabetes 
use either alloxan or streptozotoccin. These drugs 
selectively destroy B-cells of the pancreas and hence prevent 
insulin production. The diabetic state can be studied in 
either acute or chronic stages: for acute diabetes, animals
are given a relatively high dose of diabetogen (> 60mg/kg 
for streptozotoccin) and studied 2-4 days later. In the 
chronic state, a lower dose of drug is used (< 60mg/kg 
streptozotoccin) and the animals can be studied over longer 
periods of time (weeks or months).
Figure 1.16 
Metabolic consequences of diabetes
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b) Lipid metabolism
Diabetes causes an accumulation of myocardial 
triglycerides (Murthy and Shipp, 1977; Paulson and 
Crass, 1980). Levels of acyl-CoA + LCAC were also elevated 
and this was still evident after 60 min. perfusion with 
glucose as the only substrate (Paulson and Crass, 1982).
Such lipid metabolites have been associated with abnormal 
cardiac function (rev. Corr et al., 1984).
Increased levels of circulating free fatty acids (FFA) 
associated with diabetes in vivo may lead to an accumulation 
of TG by increased synthesis and decreased lipolysis 
(Murthy et al., 1983; Paulson and Crass, 1982). They may 
also contribute to the increased levels of LCA-CoA and LCAC 
(Neely and McDonough, 1988).
Inhibition of fatty acid oxidation with POCA can 
normalize glucose utilization and performance in acute 
diabetes (Rosen and Reinauer, 1984).
c) Ischaemia and reperfusion
Increases in the levels of LCAC and acyl CoA during 
ischaemia have been implicated in myocardial dysfunction 
(Corr et al., 1984). In diabetes, there is a higher level 
of these metabolites, and on induction of ischaemia, a 
greater increase in the concentration of LCAC occurs than 
is seen in normals. (Feuvray et al., 1979).
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In isolated perfused hearts from acutely diabetic 
rats, mild ischaemia was tolerated to the same extent in 
both normal and diabetic hearts. However, severe 
ischaemia caused a faster rate of ventricular failure in 
diabetic hearts; this was associated with a more rapid rise 
in the levels of acyl-CoA and LCAC (Feuvray et al., 1979).
However, reperfusion of diabetic hearts leads to a
better recovery than normals: Tani and Neely (19 88) exposed
hearts from normal and diabetic rats to 30 min. global
ischaemia and 30 min. reperfusion. Recovery (measured
on developed pressure and heat rate) was better in the
diabetic hearts. They suggested that this was due to a 
2+depressed Ca uptake on reperfusion (measured using 
45 2+Ca ) of diabetic hearts.
d) Lipolysis
Perfusion of isolated hearts from diabetic rats with 
substrate-free or glucose only buffer produces faster rates 
of lipolysis compared with normal hearts. This is measured 
as a more rapid mobilization of radiolabelled triglyceride 
(Paulson and Crass, 1982; Murthy et al., 1983) or increased 
glycerol release (Rosen et al., 1981a). However, if the hearts 
are perfused under 'diabetic' conditions i.e. increased levels 
of FFAs, no such increase is observed (Paulson and Crass,
1982).
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Regulation of lipolysis in the diabetic heart is, 
however, poorly understood, and conflicting results have 
been obtained: Rosen et al., (1981a), using acutely
diabetic hearts perfused with glucose only, found a 
decrease lipase activity at pH7.4 (TGL) which could be 
restored with insulin in vivo. They also found that 
perfusion of isoproterenol led to the same stimulation of 
lipolysis (-2 fold) in both normal and diabetic hearts.
Kenno and Severson (1985), using myocytes isolated from 
acutely diabetic hearts, found isoproterenol produced only 
a small increase in lipolysis (1.2 fold compared with 
2-fold in normals). Further work found an increase in 
neutral lipase (TGL) activity and a decrease in LPL activity 
(Ramirez and Severson, 1986).
e) Esterification
There are no reports on the effects of diabetes on
triglyceride-synthesizing enzymes in heart. In rat adipose
2+tissue, the activities of GPAT, MGPAT, Mg -dependent PPH 
and FAS were all reduced in diabetes, whereas DGAT activity 
was^unchanged. (Saggerson and Carpenter, 1987). Both 
mitochondrial and microsomal GPAT activities were depressed 
in this study; 2 day treatment with insulin in vivo 
returned FAS to control levels and GPAT, MGPAT and PPH to higher 
than control levels - this effect could be observed after only 
2 h. of treatment. If the cells were homogenized in buffer 
containing albumin, the insulin-induced restoration of PPH
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activity was abolished, but not that of GPAT (Taylor and 
Saggerson, 1986) suggesting different mechanisms are 
involved.
In liver of diabetic rats, no change or a slight 
increase in GPAT activity has been observed (Bates and 
Saggerson, 1977; Dang et al., 1984).
f) Adrenergic receptors
The number of 8-receptors in diabetic rat heart is 
reduced (Savarese and Berkowitz, 1979). Heart protein 
yield and density of muscarinic receptors was not 
altered suggesting a true down-regulation of 8-receptors 
(Ramanadham and Tenner, 1987).
There is less evidence available for a-receptors, but 
Heyliger et al., (1982) found a decreased response to the
a-agonist methoxamine in diabetic rat papillary preparation.
During diabetes there is an increase in the concentration 
of circulating catecholamines (Christensen, 1974; Paulson 
et al., 1980). It has been shown with various cell types 
that long term exposure to 8”a<?onists leads to a reduction 
in g-receptor number together with a decrease in responsiveness 
to a further challenge with the agonist (Mickey et al., 1975; 
Tse et al., 1979). Thus increased catecholamine levels in 
diabetic rats could down-regulate cardiac 8-receptors and 
alter their responsitivity to agonists (Bitar et al., 1987) .
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i) Phosphorylase
Isoproterenol-stimulated adenylate cyclase activity 
and cAMP generation were found to be reduced in diabetic 
rat hearts (Atkins et al., 1985; Gotzsche, 1983). However, 
Vadlamudi and McNeill (19 83) found that basal cAMP levels 
were unchanged in diabetes.
There is a general agreement that B-agonists produce
a supersensitive activation of phosphorylase in hearts
from acutely diabetic rats (Vadlamudi and McNeill, 1983;
Miller et al., 1981; Ingebretsen et al., 1981) which may be
2+due, at least partially, to increased Ca levels in the 
diabetic heart.
^  2+g) Ca__
A number of observations have suggested an alteration 
2+in Ca homeostasis in the diabetic myocardium. For example,
diabetic hearts have a reduced inotropic response to 
2+increased [Ca ] (Biefeld et al., 1983) and also a reduced 
2+Ca uptake on stimulation with isoproterenol (Gotzche, 1983)
- f  2  +In addition, the Na K ATPase and Ca ATPase activities are
depressed (Heyliger et al., 1987; Pierce et al., 1982) and
the isoenzyme distribution of myosin ATPase shifts from the
normally predominant to the less active form (Garber
et al., 1983) .
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The increase in LCAC levels during acute diabetes
2 +have been found to inhibit the Ca ATPase in isolated
sarcoplasmic reticular preparations (Lopaschuk et al., 1983).
2+Therefore, the amount of Ca available for release may be
lower than normal and contribute to the altered contraction
observed in diabetic hearts. Treatment with insulin
2+normalized LCAC levels, Ca uptake by the sarcoplasmic 
reticulum and heart function (Lopaschuk et al., 1983).
2+
Carnitine treatment also normalized LCAC levels and Ca 
uptake, but heart function was not improved (Vadlamudi et al., 
1982). Methylpalmoxirate (an inhibitor of CAT^) had the 
same effect as carnitine (Tahiliani and McNeill, 1985).
METHODS AND MATERIALS
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2 .1 Perfusion of hearts
a) Perfusion apparatus
The perfusion apparatus consists of a modified 
Langendorff system (Broadly, 1979) (figure 2.1). The system 
consists of water-j acketed. glassware connected by polythene 
tubing, the perfusate being pumped by a variable speed 
peristaltic pump using silicone tubing at the pump.
To calibrate the flow rate, the perfusate leaving the 
cannula was collected in a measuring cylinder and the volume 
emerging recorded over a 2 minute interval. The pump speed 
was adjusted to obtain a flow rate of 10 mls/min. Air 
bubbles were removed from the system by the bubble trap.
A thermostated recirculating pump supplied heated water 
from a reservoir to the water jacketed glassware. The 
thermostat was adjusted so that the temperature of the 
perfusate leaving the cannula was 37°C. The perfusate was 
filtered before entering the heart by a prefilter and filter 
and was aerated by being gassed with 95% 0^/5% CO^ before 
entering the circulation system.
b) Procedure
Male albino rats, Wistar strain, weighing 200-250g bed 
ad libitum on laboratory chow (Oxoid 41B) were used. Animals 
were stunned and their hearts rapidly removed and placed in 
ice-cold Krebs-Henseleit buffer (Krebs & Henseleit, 1932):
NaCl - 118mM, NaHC03 - 25mM, KC1 - 4.7mM, glucose - 11.6mM,
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Figure 2.1 
Heart perfusion system
H
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Components of the perfusion system
A — pump
B - filter
C - heating coil
D - bubble trap
E - heart
F - water jacket
G - water at 37°C
H - transducer
I - % collecting funnel
J - 95% 02/5% C02
K - perfusate
L _ manometer
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KH2P04 - 1.2mM, MgS04.7H20 - 1.2mM, CaC^.6H20 - 1.25mM,
pH 7.4. This cold buffer arrested the heartbeat.
The heart was rinsed free of blood and extraneous 
pericardial adipose tissue removed. The aorta was attached 
to a vinyl cannula with an artery clip and immediately 
perfused with Krebs-Henseleit buffer at 37°C. The aorta was 
then tied to the cannula with a silk suture. Contractility 
was monitored with a Dynamometer UF2 transducer; a thread 
was attached to the apex of the heart by a small nickel hook 
and the thread attached to the Dynamometer by way of a pulley 
wheel. Developed tension of the heart could then be recorded 
after resting tension had been set at 2g. Heart rate was 
measured manually using a stop watch up to -250 beats/min; 
for higher rates the chart speed on the recorder was increased 
to obtain discrete beat patterns.
Following 20 min. perfusion, hearts were removed and 
placed in ice-cold Krebs-Henseleit buffer. The atria and 
aorta were transected from the ventricles and ventricular 
muscle was then homogenized in -8ml ice cold STE(F) buffer: 
.25M sucrose, lOmM Tris, ImM EDTA (50mM NaF), pH 7.6 for 
3 x 5s by a Polytron homogenizer (setting 3.5).
c) Perfusion procedure for studying the effects of 
various drugs
i) adrenaline
18.3mg adrenaline was dissolved in 100ml Krebs-Henseleit
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-3
buffer (to give a concentration of 10 M). This was then 
diluted to give 10 M adrenaline. 0.5ml of 10 M 
adrenaline was injected into the perfusion system at the 
point just before entry of perfusate into the bubble trap. 
The heart was removed 1 min. following addition of 
adrenaline. The solution of adrenaline was prepared just 
before use and discarded after 1 hour.
2+ii) Ca antagonists
Diltiazem and verapamil were dissolved in Krebs-
-3
Henseleit buffer to give a concentration of 10 M. 500yl
-3
10 M diltiazem was added to 500ml perfusate to give a final
_ 6 _ 3
concentration of 10 M. 50pl 10 M verapamil was added to
-7
500ml perfusate to give a final concentration of 10 M. 
Nifedipine was dissolved in absolute ethanol to give a
-3
concentration of 10 M. 50yl of this solution was then
added to 500ml perfusate to give a final nifedipine
-7
concentration of 10 M (the final concentration of ethanol
in the perfusate was .01%).
Normal perfusion was carried out for 15 min. before the
perfusate was switched (by means of a 3-way tap) to one
2+containing the required Ca antagonist for 5 min., at which 
time hearts were removed.
iii) TPA
TPA was dissolved in dimethylsulphoxide at a 
concentration of 2 x 10 and stored below 0°C in 20yl 
aliquots. For perfusion studies, 380pl Krebs-Henseleit
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buffer was added to the 20yl aliquot. After vortexing,
the 400yl of TPA solution was added to 400ml perfusate to
-7
give a final TPA concentration of 10 M. (Gloves were 
worn when handling any solution containing TPA).
Hearts were perfused normally for 15 min. before 
switching to perfusate containing TPA for 5 min.; at this 
time hearts were removed.
d) Procedure for studying the effects of ischaemia and 
reperfusion
i) Regional ischaemia
Hearts were perfused normally for 10 min. after which 
time a silk suture was inserted behind the left descending 
coronary artery using a curved needle (length 16mm). The 
artery was occluded by ligation of the suture. The ischaemic 
area of the left ventricle is clearly visible after 10 min. 
occlusion at which time hearts were removed and placed in ice- 
cold Krebs-Henseleit buffer. Tissue samples (-lOQmg) were 
quickly dissected from the left (ischaemic) and right (non- 
ischaemic) ventricles. The samples were homogenized 
separately in 3ml ice cold STE buffer.
For reperfusion studies, a 4mm length of polythene 
tubing was inserted between the artery and suture just before 
ligation. This tubing was removed after 10 min. occlusion 
allowing reperfusion of the artery. Tissue samples were 
taken from previously ischaemic and non-ischaemic areas at
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1 min. and 5 min. after reperfusion had begun.
ii) Global ischaemia 
Perfusion was carried out normally for 10 min. The 
pump was then switched off and a clamp (which had been 
previously placed just above the cannula) tightened. For 
ischaemic studies, the heart was removed after 10 min. For 
reperfusion studies, the clamp was loosened and the pump 
restarted. The heart was then removed after 1 min. or 5 min. 
of reperfusion.
e) Sterilization, and washing of the perfusion apparatus 
To avoid bacterial contamination the apparatus was 
filled with an antibiotic mixture of penicillin (300 U/ml), 
streptomycin (lmg/ml) and neomycin (lmg/ml) overnight.
This was drained and distilled water pumped through the 
system before continuing perfusions.
After approximately 20 perfusions, the apparatus was 
disconnected and the components washed first in chromic 
acid and then in Decon .700 detergent. This was followed 
by rinsing with distilled water. At the same time all 
the vinyl tubing and 3-way taps were replaced.
2.2 Extraction of enzyme
After homogenization of the ventricular tissue, the 
homogenate was either used directly as a crude GPAT preparation 
or centrifuged in a bench centrifuge for 5 min. at 2000g, 4°C. 
The supernatant was used as a crude TGL preparation.
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For preparation of mitochondria, the 2000g 
supernatant was centrifuged at 10 OOOg for lOmin., 4°C 
(Sorvall RC 5B, 8 x 50ml head). The supernatant was 
kept for preparation of a microsomal fraction and the 
pellet washed with STE(F) buffer and centrifuged again.
This pellet was resuspended in 5ml of STE(F) plus 1% 
defatted BSA to give a final protein concentration of 
2-3mg/ml. This preparation was used for the mitochondrial 
form of GPAT and assay of CAT^.
The 10 OOOg supernatant was centrifuged at 200 OOOg for 
30 min., 4°C (Beckman L5-50B ultracentrifuge, SW 50.1 rotor). 
The pellet formed was resuspended in 0.5ml STE(F) at a 
protein concentration of 1.0-1.5mg/ml. This was used to 
assay the microsomal form of GPAT.
A portion of the 10 OOOg supernatant (1ml) was retained 
for assay of glycogen phosphorylase.
2.3 Incubation with N-ethylmaleimide
200yl of crude homogenate, mitochondrial or microsomal 
fraction was incubated in the absence or presence of 15mM 
N-ethylmaleimide (NEM) for 5min. at 30°C. Each fraction was 
assayed for GPAT activity. NEM-sensitive activity was 
calculated as that due to the microsomal form of the enzyme. 
NEM-insensitive activity (mitochondrial GPAT) was calculated 
as the difference in activity between that measured in absence 
and presence of NEM.
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2.4 Incubation with cAMP-dependent protein kinase 
Freshly perfused rat heart homogenate, mitochondrial
or microsomal fraction was incubated at 30°C for 15 min. 
in STE buffer with, when included, lOmM MgCl2, 5mM ATP,
5yM cAMP, O.lmg cAMP-dependent protein kinase in a final 
volume of 200yl. Samples were assayed for GPAT activity 
immediately after incubation.
2.5 Incubation under dephosphorylation conditions
This method relies on the activation of endogenous
2+ 2+phosphoprotein phosphatases by Ca and Mg (Severson 
et al 1977).
To 500yl homogenate or supernatant were added 50yl 
lOGmM MgCl2, 50yl 120mM EGTA, 50yl 120mM CaCl2, lOOyl lOOmM 
MOPS, pH 7.0. The mixtures were vortexed and incubated at 
30°C for 30min. Samples were assayed, for GPAT or TGL 
activity, immediately after incubation. Control incubations 
contained the same reagents except MgCl2 and CaCl2 (200yl 
water was added instead).
2.6 Incubation with TPA
Homogenate or supernatant was incubated for 15 min. at 
30°C in STE buffer with, when included, lOmM MgCl2.6H20,
5mM ATP, pH 7.6, lOOyM CaCl2, 10 ^M TPA and 20yg/ml
phosphatidylserine in a final volume of 200yl. Samples were
assayed immediately after incubation for GPAT and TGL activity.
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These conditions favour activation of endogenous 
protein kinase C (Castagna et al, 1982).
i) Preparation of phosphatidylserine (PS)
5mg PS were dissolved in a small volume (~0.5ml) 
chloroform which was then removed in vacuo. The precipitate 
was resuspended in a small volume of Tris/HCl pH 7.5 and 
then the volume made up to 12.5ml (this gave a PS concentration 
of 400|jg/ml). This was then sonicated on ice for 5 min. in 
15s. bursts (100w, using a 1cm probe). The solution was 
aliquoted out and stored at 4°C.
2.7 Diabetes
a) Induction of diabetes
Male wistar rats (200 - 250g) were starved for 24h. before 
induction of diabetes by a single tail-vein injection of 
streptozotocin (120mg/kg) dissolved in lOmM Na citrate 
(lOQmg/ml), pH 4.2. The solution was prepared immediately 
before use.
Hearts were isolated 48h after the injection and perfused 
as before.
b) Blood glucose measurement
Blood glucose levels were determined by the method of 
Asatoor and King (1954).
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The solutions required are as follows: 
Cu reagent
Hardings reagent
- 3g CuS04.5H20 in 500ml H20
- Dissolve in order 6g NaK tartrate, lOg 
Na^O^, 12.5g NaHCO^ 9g K oxalate in 
500ml H20
Nelson's reagent - Dissolve lOg ammonium molybdate in 180ml
H20. Slowly add 8.4ml conc. H^O^. 
Dissolve in 10ml H20 1.2g Na arsenate 
(Na2HAs04.7H20) then add to solution and 
make up to 200ml. Store at 37°C.
The procedure is as follows:
(i) Take lOOpl blood and add 1.5ml H20, 0.2ml 0.15M 
Ba(0H)2, 0.2ml 5% ZnS04.3H20. Vortex and spin at 2000 rpm. 
Keep supernatant. Diabetic rats will require blood to be 
diluted, so use only lOOyl supernatant in step (iii).
(ii) Prepare glucose standards (0-100yg) using a stock 
solution of 0 .lmg/ml, in a final volume of 1ml.
(iii; To 1ml final volume (supernatant or glucose standard) 
add 1ml Cu-reagent and 1ml Hardings reagent. Vortex and boil 
for 20 min.
(iv) Cool, add 1ml Nelson's reagent and 6ml H20.
Read absorbance at 600nm.
2.8 Determination of protein content
The method used was that of Bradford (1976) with bovine 
serum albumin as standard.
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50mg Coomassie blue G-250 was dissolved in 25ml 95% 
ethanol. To this was added 50ml orthophosphoric acid and 
the volume made up to 500ml with double distilled water.
The solution was filtered twice through Whatman filter paper 
(no. 1) before use. 2ml of this solution was added to 
lOOyl of the test protein (<30yg) and the absorbance read at 
595nm.
2.9 Determination of enzyme activities
a) Glycerol 3-phosphate acyltransferase (GPAT)
The principle of the method (Evans, 1977) is as follows:
GPATlong chain acyl CoA + G3P monoacyl G3P + CoA
MGPATmonoacyl G3P + long chain acyl CoA diacyl G3P + CoA
G3P - glycerol 3 phosphate; MGPAT - monoacylglycerol 
3 phosphate acyltransferase - not rate limiting
The assay was carried out at 30°C in a final volume of
lOOyl containing 0.25M sucrose, lOmM Tris, ImM EDTA
5GmM KC1,pH 7.4, O.lmM palmitoyl CoA, 0.3mg BSA (defatted)
14and 0.5mM [U- C] glycerol 3-phosphate (O.lyCi). The reaction 
was initiated by addition of lOyl homogenate (-40yg protein), 
mitochondrial (~25yg) or microsomal (~12.5yg protein) fraction.
The reaction was stopped after 5 min. by addition of 
500yl trichloroacetic acid (TCA; 10% w/v) - saturated butanol.
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The solution was vortexed and the layers separated by 
centrifugation in an Eppendorf microfuge for 2 min. The 
lower aqueous layer was removed with a Gilson pipette set at 
llOyl and the butanol layer washed with 1ml butanol-saturated 
TCA. After a further centrifugation, a lOOyl sample of the 
butanol layer was dissolved in 2ml scintillation fluid (600ml 
Triton, 1400ml toluene, lOg PPO). Each time point was done 
in triplicate. A zero time point was measured and subtracted 
from the measurement at 5 min. Radioactivity was counted in 
a Tricarb. liquid scintillation counter.
.b) Triglyceride lipase (TGL)
The activity of TGL was determined by a modification of 
the method of Severson (19 79).
14The glycerol tri (1- C oleate (triolein) substrate,
9.2mM in hexane (specific activity 1.6yCi/mM) was dried 
under nitrogen and resuspended in an equal volume (3.125ml) 
of absolute ethanol. A solution of 264mg triolein in 1ml 
hexane was prepared and 0.1ml added to 3.025ml absolute 
ethanol. This was used to increase the concentration of 
triolein in the radioactive aliquots. lOyl 'hot' triolein 
and lOyl 'cold' triolein were mixed together just before use.
The assay was carried out in a final volume of 80jjl 
14containing 0.35mM C-triolein (.16nCi) 50mM sodium phosphate 
and 0.08mg albumin pH 7.5. This suspension was sonicated 
for 30s. immediately before use. The reaction was initiated
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by the addition of 20yl supernatant (~40yg protein). Each 
time point was done in triplicate.
After 30 min. the reaction was stopped by the addition 
of 300yl of a solvent system containing methanol:chloroform: 
heptane (1.41:1.25:1) and O.lmM oleic acid (which acted as 
carrier). lOyl NaOH was also added. The mixture was 
vortexed vigorously and centrifuged in an Eppendorf microfuge 
for 3 mins. A 50yl aliquot of the upper, aqueous layer was 
dissolved in 4ml scintillation fluid with 5yl HC1 and then 
counted.
c) Carnitine palmitoyl transferase (CPT)
This method is based on that of Saggerson, (1982).
CPT
Pal CoA + L(-) carnitine + Pal-carnitine + CoA
The assay was carried out at 30°C in a final volume of
lOOyl containing 0.25M sucrose, lOmM Tris, 5QmM KC1, ImM EDTA,
14pH 7.4, with 0.5mM DL-(methyl- C)-carnitine hydrochloride 
(.05yCi), 50yM Pal-CoA and .02mg defatted BSA. The reaction 
was initiated by addition of lOyl mitochondrial fraction 
(-25mg protein).
After 3 min. the reaction was stopped by addition of 
50yl 6M HC1; 300yl of water-saturated butanol was then added. 
After vortexing, the layers were separated by centrifugation 
in an Eppendorf microfuge for 2 mins. The aqueous (lower) 
layer was removed while the butanol layer was washed with
74
750yl butanol-saturated water. After vortexing and a 
further centrifugation, lOOyl of the butanol (upper) layer 
was dissolved in 2ml scintillation fluid. Each time point was 
done in triplicate. Radioactivity was counted in a Tricarb 
scintillation counter.
d) Glycogen phosphorylase
i) Gel filtration
AMP is a potent activator of phosphorylase so in order 
to distinguish between activation by phosphorylation and 
increases in AMP concentration, endogenous AMP was removed 
from the extract before assaying.
A prepacked column of Sephadex G-25 (PD-10), dimensions 
5 x 1cm (Pharmacia) was equilibriated in 50ml STE(F) at 4°C.
The gel bed was drained and 0.85ml 10 OOOg supernatant layered 
onto the column. Once the extract had permeated the gel base, 
the column was eluted with STE(F). 0.9ml fractions were 
collected manually and the first 0.9ml eluate that contained 
protein (estimated by the colour difference) was used for 
the phosphorylase assay.
ii) Assay
Phosphorylase was assayed in the direction of glucose-1- 
phosphate by a spectrophotometric assay based on that of 
Mendicino et al (1976). The principle of the assay is as 
follows: Glucose 1-phosphate (Glu-1- P ) produced by
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phosphorylase is isomerized to Glu-6- P which is then 
oxidized to 6-phosphoglucano-6-lactone by NADP+ .
Phosphorylase
(a 1,4-glucoside) + P. ------------> (al,4 glucoside)n 1 n—l
+ a-D glucose 1- P 
2 +Glu 1,6 diphosphate, Mg 
aD Glu-1- P  > aD-Glu-6- P
Phosphoglucomutase
Glu 6- P dehydrogenase 
a-D-Glu-6- P -—  — ^ 6 phosphoglucano-6-lactone
+ NADPH + H+
NADPH production is estimated at 340nm.
Enzyme assays were performed at room temperature in a 
Cecil CE 272 single beam uv/visible region spectrophotometer 
at 340nm. Absorbance changes were monitored continually on 
a Rikandenki chart recorder.
Assays were carried out in 1ml plastic cuvettes
in a final volume of 1ml containing: 50mM imidazole,
lOmM MgCl2, 2mM EDTA, pH 7.0, 0.lmg/ml BSA, 0.4mg/ml protamine
sulphate, 70mM potassium phosphate, 0.3mM NADP+ , 10yM Glu 1,
6 diphosphate, 3.26 ymol/min Glu 6 P dehydrogenase,
4.9 ymol/min phosphoglucomutase, 0.3mg/ml glycogen and ImM 
AMP.
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All components, except AMP, were added to the cuvette. 
The reaction was initiated by the addition of lOyl extract 
(-15yg protein). After the AMP-independent rate had been 
obtained, AMP was added to the cuvette and the new rate 
measured. This gave an estimate of total phosphorylase 
(a and b) activity.
2.10 Calculation and analysis of results
Statistical analysis was performed using Student's 
t-test. Values are presented as means ± standard error 
(S.E.).
a) GPAT
GPAT activity is expressed as nmold/min/mg protein
sample count x standard x i . . , x . x 500
standard count time (min) yg protein y-yr
in aliquot
Standard count was measured by taking 10 yl from the assay 
mixture, adding 2ml scintillation fluid and counting.
b) TGL
TGL activity is expressed as nmole/min/mg
sample count n , 1 1000 210. rj 5----  . x nmoles in standard x   x — — . . x — —standard count time yg protein m  50
aliquot
Standard count was measured by taking lOyl from the assay 
mixture, adding 4ml scintillation fluid, vortexing and counting.
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c) CPT
CPT-^  activity is expressed as nmole/min/mg
sample count , , j 1 1000 306r j -^---  , x nmoles in standard x — --  x ----   . x — —standard count time yg protein 100
To calculate the standard count, lOyl of the assay mixture 
was added to 2ml scintillation fluid, vortexed and counted.
d) Glycogen phosphorylase
Phosphorylase activity is expressed in terms of rate in 
the absence of AMP/rate in presence of AMP (the -AMP/+AMP 
ratio) which is proportional to the amount of phorphorylase a,
In order to obtain an estimate of the -AMP/+AMP ratio 
the enzyme was incubated at 0°C and assayed at various intervals 
(^8 min.) for 3-4h. following removal of the heart from the 
perfusion apparatus.
It was found that -AMP/+AMP ratio declined even with time. 
It was assumed that this linear decline had been constant 
since heart homogenisation and the initial rate was calculated
i
by back extrapolation using linear regression.
2.11 Materials
a) Equipment
.45ym membrane filters were obtained from Sartorius GmbH, 
Gottingen, West Germany or from Millipore, London. 2.5ym
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prefilters were from Millipore. The membrane filter housing 
was a Millipore Swinnex 25.
The peristaltic perfusion pump was from Watson Marlowe, 
Falmouth, U.K. Silicone tubing for the pump and glass to 
polythene tubing connections were from Watson Marlowe,
Falmouth, Cornwall - internal diameter 3.2mm, external 
diameter 6.4mm. Polythene transmission tubing (i.d. 0.86mm, 
o.d. 4.8mm) was supplied by Portex Ltd., Hythe, Kent.
Perfusion glassware was obtained from Jencons Ltd.,
Hemel Hempstead, Herts. Physiological recorders were from 
Devices Instruments Ltd., Welwyn Garden City, Herts.
Tricarb liquid scintillation counter was from Packard 
Instruments Ltd., Caversham, Berks. Polytron homogenizer 
was obtained from Northern Media Supply Ltd., North Humberside.
Sorvall RC-5B refrigerated superspeed centrifuge was 
obtained from Dupont Company, Connecticut, U.S.A.
Beckman L5-50B ultracentrifuge was from Beckman Instruments, 
California, U.S.A.
Sephadex G.25 columns were supplied by Pharmacia-LKB, 
Uppsala, Sweden.
79
b) Chemicals
Laboratory chemicals were Analar grade from BDH Ltd., 
Poole, Dorset.
Radiochemicals were obtained from the Radiochemical Centre, 
Amersham, Bucks.
All drugs, enzymes, substrates and cofactors were 
supplied by Sigma Chemical Company Ltd., Poole, Dorset, 
except for glycogen (AMP-free) and NADP (disodium salt) 
which were from Boehringer-Mannheim, Lewes, U.K.
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2.12 Characteristics of enzyme assays
a) Triglyceride lipase (TGL)
The heart contains several lipase activities (Severson, 
1979; Stam et al., 1986); an acid lipase can be 
distinguished easily on the basis of its pH optimum (4.8). 
However, it is more difficult to distinguish between 
endogenous lipoprotein lipase (LPL) activity and neutral 
triglyceride lipase (TGL) activity. Work from this 
laboratory (Al-Muhtaseb, 1982) and elsewhere (Severson, 1979; 
Ramirez et al. , 1985) has identified a lipase with properties 
distinct from those of LPL.
The assay for TGL activity used in this thesis was 
developed by Al-Muhtaseb (1982). The major characteristics, 
which are in general agreement with those found by Severson 
(1979), are summarized below.
i) Assay buffers
Optimal assay conditions were as follows: TGL -
phosphate buffer and 1% BSA, pH 7.5 (inhibited by serum;
LPL - tricine buffer with 1% BSA, pH 8.2 (stimulated by serum).
ii) Protamine sulphate
lmg/ml protamine sulphate stimulated TGL activity and 
inhibited LPL activity.
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iii) Heparin
Heparin had no effect on TGL activity, but at 
20yg/ml stimulated LPL activity.
iv) Chloroquine
TGL activity was stimulated at both 1 and 15mM 
chloroquine. At higher concentrations (> 20mM) it was 
inhibited. LPL activity was essentially inhibited at all 
concentrations of chloroquine.
v) NaCl
.06M to .4M NaCl had no effect on TGL activity, but at 
.6M NaCl it was inhibited. LPL activity was inhibited 
at all concentrations of NaCl.
vi) Effect of substrate concentration
14Increasing the concentration of ( C) triolein 
increased the rate of reaction up to .46mM. This gave a 
Km of .4mM.
vii) Effect of incubation time and enzyme 
concentration
Figure 2.2 shows that the TGL assay is linear over 
45 min. In subsequent assays the enzyme activity was 
measured at 30 min.
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Figure 2.2
Effect of incubation time on TGL activity
Number of observations at each point = 6 
Values are means - S.E.
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Heathers et al. (1985) showed that the assay was 
linear up to at least lOOyg protein per assay. In 
subsequent assays 20-40yg protein was added per assay.
b) Glycerol 3-phosphate acyltransferase (GPAT)
In heart and other tissues, triglyceride synthesis 
occurs on the outer surface of the reticular system 
(endoplasmic or sarcoplasmic reticulum) (Bell and Coleman, 
1983) . Myocardial GPAT has been studied in this 
laboratory for several years. Other workers have focussed 
on adipose tissue and hepatic GPAT (Nimmo and Nimmo, 1981; 
Rider and Saggerson, 19 83). Generally it has been assumed 
that the triglyceride synthesis pathway in heart is similar 
to that of adipose tissue.
The assay, method employed here is that described by
14Al-Muhtaseb (1982) using ( C)-glycerol-3-phosphate and 
palmitoyl-CoA as substrates.
i) Effect of incubation time and enzyme 
concentration
GPAT activity was measured in ventricular homogenates. 
The assay was linear with time up to only 6 mins. (Figure 
2.3). Possible reasons for this are exhaustion of one of 
the substrates or end product inhibition. An incubation 
time of 5 min. was adopted as routine in subsequent assays 
on homogenate.
Figure 2. 3
Effect of incubation time on GPAT activity
Number of observations at each point = 6 
Values are means - S.E.
(GPAT activity was measured in crude homogenate)
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Heathers et al. (19 85) found that assays were linear
up to at least 130yg protein per assay. Subsequently, 
50-70yg protein was used per assay.
ii) Effect of substrate and alburnin concentration
Concentrations of palmitoyl CoA (pal CoA) up to lOOyM 
increase the rate of reaction (Al Muhtaseb, 19 82) but above 
this concentration the rate decreases slowly. A Km of 
50yM was obtained.
14Increasing [ C-G3P] up to ImM increased the reaction 
rate giving a Km of 0.5mM.
[BSA] up to 2mg/ml stimulated GPAT activity but at 
higher concentrations the rate declined slowly (Al-Muhtaseb, 
1982).
iii) Identification of lipid end products
Al-Muhtaseb (19 82) found that the majority (79%) of 
the end product was phosphatidate with little accumulation 
of triglyceride or monoacylglycerol phosphate. This was 
studied by thin layer chromatography of whole heart 
homogenate.
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c) Phosphorylase
The rate of reaction was found to be linear with time 
up to at least 10 min. This rate was dependent on the 
presence of all assay components except AMP (which stimulated 
the measured rate) and protamine sulphate (which was included 
to inhibit phosphorylase phosphatase - Ball and Fischer, 1986). 
The assay rate was proportional to protein concentration over 
the range used (< 30yg/assay) . Subsequently, -20yg protein 
was added per assay.
The phosphorylase activity in extracts of hearts 
homogenised in STE declines at 0°C and this decline was 
markedly curved (Figure 2.4). Inclusion of 50mM NaF in 
the homogenization and gel filtration buffers reduced the 
magnitude of the decline and produced a linear rate - 
(Figure 2.4). Since NaF is a phosphatase inhibitor, this 
result suggests that the decline in activity observed in 
hearts homogenised in STE was due to endogenous phosphatase 
action on phosphorylase. Since analysis of results by 
linear regression was possible, NaF was routinely included 
in phosphorylase extraction buffers.
(N.B. Results in Figure 2.4 are from hearts treated 
with lyM adrenaline. )
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Figure 2.4
Effect of NaF on phosphorylase activity
Adrenaline treated hearts were homogenised in absence or presence of 
NaF and phosphorylase activity determined following gel filtration as 
described in "Methods".
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d) Carnitine acyltransferaseT (CAT )-------------------------------j------ j—
The assayed employed is based on that of Saggerson 
(1982).
i) Incubation time
Figure 2.5 shows that the rate of reaction is linear 
up to at least 3 min. Subsequently an incubation time of 
2 min. was adopted as routine.
ii) Enzyme concentration
Heathers (1985) found that the assay was linear up to 
at least 40yg protein per assay. In the experiments 
described here, -25yg protein was added per assay.
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Figure 2.5
Effect of incubation time on CAT activity
Number of observations at each point = 4 
+
Values are means - S.E.
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3.1 GPAT activity in subcellular fractions
In adipose tissue, GPAT activity exists in both 
mitochondrial and microsomal fractions (Saggerson et al., 
1979). The two activities have distinct properties, most 
noteably they show different sensitivity to sulphydryl 
reagents such as N-ethylmaleimide (NEM): in rat adipose 
tissue, NEM inhibited GPAT activity in the microsomal, but 
not mitochondrial fraction (Saggerson et al., 1980).
Subcellular fractions were prepared from perfused hearts 
as described in 'Methods'. Table 3.1 shows GPAT activity 
in the various fractions. The highest specific activity 
was found in the microsomal 200 OOOg pellet where the 
activity was approximately 10-fold higher than that of the 
crude homogenate. .........
The microsomal pellet was extracted at a protein 
concentration of 1 - 1.5mg/ml (above 1.7mg/ml the assay was 
not linear with respect to enzyme concentration (Figure 3.1)).
Heathers et al (19 85) used NEM in homogenates of rat 
heart to distinguish between microsomal and mitochondrial 
activity. Samples of homogenate, mitochondrial or 
microsomal fractions were incubated - 15mM NEM for 5 min. at 
30°C as described in 'Methods'. GPAT activity was measured 
immediately after the incubation and the results are shown 
in Table 3.2. It is clear that inhibition of GPAT activity
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Table 3.1
GPAT activity in subcellular fractions
Fraction GPAT activity (nmoles/min/mg)
Crude homogenate .57 - .08 (6)
2000g supernatant .41 - .09 (6)
10 OOOg supernatant .72 - .14 (4)
10 OOOg pellet .56 - .06 (6)
200 OCOg pellet 5.27 - .40 (5)
Hearts were perfused for 20 min. before homogenisation in STE 
buffer. GPAT activity was measured in various subcellular 
fractions as described in "Methods".
Results are means - S.E., number of observations shown in 
parentheses.
Figure 3.1 Effect of protein concentration on microsomal GPAT activity 
Each point represents the mean of 2 observations
120 -
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Table 3.2
Effect of N-ethylmaleimide on mitochondrial and microsomal
GPAT activity
GPAT activity (nmoles/min/mg)
Fraction -NEM +NEM
Crude homogenate .58 - .07 (4) .38 - .05(4)*
Mitochondrial .69 - .05 (5) .64 - .05 (5)
Microsomal 5.69 - .47 (4) 1.15 - .23 (4)**
Hearts were perfused for 20 min. and subcellular fractions prepared 
as described in "Methods". Extracts were incubated - 15mM N-ethyl­
maleimide for 5 min. at 30°C before measurement of GPAT activity.
Results are means - S.E., number of observations shown in 
parentheses. Statistical significance (v activity in absence of 
NEM), p< .001; p< .005.
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occurs in botn homogenate and microsomal fraction (35% and 
80% inhibition, respectively) but not in the mitochondrial 
fraction.
3.2 Adrenergic effects on enzyme activity
a) Effect of perfusion with adrenaline on heart
performance and the activation of TGL and GPAT
Hearts were perfused normally for 20 min. before
_ g
exposure to 10 M adrenaline for 1 min. as described in 
'Methods'. From Table 3.3 it can be seen that adrenaline 
increases both heart rate and developed tension, by 33% and 55% 
respectively. TGL activity is increased by 50% and GPAT 
activity (in crude homogenate) is depressed by 35%.
Activity of GPAT in the mitochondrial fraction is 
statistically unchanged by adrenaline (Table 3.3). However, 
microsomal GPAT activity is depressed by 16% - ,a statistically 
significant amount.
b) Effect of homogenization in NaF on GPAT activity
Isolation of the microsomal pellet takes approximately
1 h after removal of the heart from the perfusion apparatus. 
During this time, in adrenaline treated hearts, a partial 
reactivation of GPAT occurs. Thus in homogenate a 35% 
inhibition is seen whereas in the microsomal fraction only a 
16% inhibition remains. To determine whether this 
reactivation was due to endogenous phosphatase activity, 
both control and adrenaline - perfused hearts were
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Table 3.3
Effect of perfusion with 10^4 adrenaline on heart 
performance and the activities of TGL and GPAT
Control Adrenaline
Heart rate (beats/min) 
Developed tension (g/heart)
227 - 17 (lO) 
4.9 ± .9 (12)
302 - 15 (6)**
* *
7.6 + 1.2 (4)
TGL activity"*
V nmoles/min/mg 
GPAT activity)
.10 - .Ol (6) .15 - .02 (6)**
Homogenate .58 - .06 (6) .36 - .03 (6)**
Mitochondrial .67 - .05 (3) .73 - .18 (3)
Microsomal 5.16 - .53 (7) 4.33 - .44 (4)*
Hearts were perfused for 20 min. without or with exposure to 
_6
10 M adrenaline for 1 min. Hearts were homogenised in STE buffer 
and enzyme activities measured as described in "Methods". 
Statistical significance:
p< .001; p< .025
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homogenized in buffer containing 50mM NaF (a phosphatase 
inhibitor).
Table 3.4 shows that in the presence of NaF, adrenaline 
produces a 36% inhibition of GPAT activity in the microsomal 
fraction. This value is similar to that for adrenaline - 
induced inhibition of GPAT in crude homogenate (35%) and 
indicates that inhibition of phosphatases allows the GPAT 
inhibition to be preserved during the isolation of the 
microsomal fraction.
c) Effect of incubation of heart extracts with cAMP, ATP 
and cAMP - dependent protein kinase on GPAT activity
Figure 3.2 shows that incubation of homogenate from 
control hearts with cAMP, ATP and cAMP-dependent protein 
kinase (cAMP-PrK) results in a time-dependent inactivation 
of GPAT with a significant inhibition from 10 min. onwards. 
The activity of GPAT incubated with buffer alone did not 
change over 30 min. This agrees with results of Heathers 
et al (1985) who found that inhibition of GPAT under 
these conditions was restricted to the microsomal 
(NEM-sensitive) fraction.
In microsomal pellet incubation with buffer alone,
GPAT activity decreases over 30 min. (Figure 3.3).
Incubating with cAMP, ATP and cAMP-PrK produces a 
statistically significantly greater inhibition at 15 min. 
and 30 min.
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Table 3.4
Effect of homogenate NaF on measured GPAT activity
GPAT activity (nmoles/min/mg)
NaF Homogenate Microsomal
Control - .62 - .04 (6)1 5.16
+
.53 (7) 5
+ .64 - .05 (4) 2 4.24
+
.30 (4) 6
i o " 6m
Adrenaline - .43 - .04 (7) 3 4.33
+ .38 (3) 7
+ .45 - . 04 (5)4 2.77
+
. 23 (4 ) 8
Hearts were perfused for. 20 min. without or with exposure to 10 M 
adrenaline for 1 min. Hearts were homogenised in STE buffer in 
absence or presence of 50raM NaF. GPAT activity was measured in 
homogenate or microsomal pellet, as described in "Methods". When 
included, NaF was present throughout extraction of one microsomal 
fraction. Results are means - S.E., number of observations shown 
in parentheses. Statistical significance: lv3, 2v4, p< .001; 5v6 
p< .01; 5v7 p< .05; 7v8 p< .001; 6v8 p< .001; other differences 
not significant.
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Figure 3.2
GPAT activity in heart homogenate incubated with 
cAMP, ATP and cAMP-PrK
Number of observations at each value = 3 
Values are means ± S.E
Statistical significance; 15 min, p <.01; 20 min, 30 min, p<
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Hearts were perfused for 20 min. before incubation of homogenate with 
A-buffer only, or B-cAMP, ATP and cAMP-PrK (see "Methods") for 15 min. 
at 30°C. Samples were taken at various time points during the 
incubation and assayed for GPAT activity.
. 001
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Figure 3.3
GPAT activity in microsomal fraction incubated with
c A M P , ATP and cAMP-PrK
Number of observations at each value = 4 
Values are means - S.E.
A statistically significant difference in activity occurs at 15 min. 
(p< .05) and 30 min. (p< .025)
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Hearts were perfused for 20 min. before isolation of the microsomal 
fraction and incubation with A-buffer only, or B-cAMP, ATP and cAMP-PrK 
(see "Methods") for 15 min. at 30°C. Samples were taken at several time 
points during the incubation and assayed for GPAT activity.
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d) Effect of incubation under dephosphorylation 
conditions on the activities of TGL and GPAT
This method relies on activation of endogenous 
2+phosphatases by Mg (Severson, 19 77). Extracts from 
control and adrenaline-perfused hearts were incubated at 
30°C for 30 min. under dephosphorylation conditions as 
described in 'Methods'.
Table 3.5 shows that in control hearts, TGL activity 
is decreased by 26% following incubation with dephosphorylation 
conditions. In adrenaline-treated compared with control 
hearts TGL is initially activated. Incubation with buffer 
alone produces a decrease in activity, but incubation with 
dephosphorylation conditions produces a greater inactivation.
In control hearts, GPAT activity is not significantly 
altered on incubation with either buffer alone or under 
dephosphorylation conditions (Table 3.6). In adrenaline- 
treated hearts, GPAT activity is depressed initially.
Incubating with buffer alone produces a partial reactivation 
but incubating with dephosphorylation conditions produce 
complete reactivation.
3.3 Phorbol Esters
Heathers et al (1985) found that perfusion of hearts 
with 8-agonists led to changes in both TGL and GPAT 
activities, but that only GPAT activity responded to a^- 
agonists.
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Table 3.5
Effect of incubation under dephosphorylation conditions on 
TGL activity from control and adrenaline-perfused hearts.
TGL activity (nmoles/min/mg)
Control Adrenaline
Initial activity .094
i—1o•
+ 
1 (6)1 .13 - .02 (4)4
30 min. incubation: 
buffer only .095 - .02 (7) 2 .094 - .02 (4)5
dephosphorylation
conditions .070
rHO 
+ 
1 (6) 3 .070 - .01 (4)6
Hearts were perfused for 20 min without or with exposure
to 10 M adrenaline before homogenization in STE buffer.
2000g supernatant was incubated with buffer alone or under
dephosphory1 ation conditions as described in "Methods" for
30 min. at 30°C before assay of TGL. Results are expressed 
+
as means - S.E., number of observations shown in parentheses. 
Statistical significance: lv3, 2v3, p< .01; 4v6, p< .025
Table 3.6
Effect of incubation under dephosphorylation conditions 
on GPAT activity in homogenates of control and adrenaline - 
perfused hearts
GPAT activity (nmoles/min/mg)
Control Adrenaline
Initial activity
30 min. incubation: 
buffer only
dephosphorylation
conditions
.59 - .05 (6) 
.58 - .15 (4) 
.65 - .19 (5)
.45 - .03 (5)1 
.54 - .07 (5)2 
.74 - .13 (4)3
Homogenates from control and 10 M adrenaline-treated hearts 
were incubated with buffer alone or under dephosphorylation conditions 
for 30 min. at 30°C as described in Methods, before assay of GPAT 
activity. Results are means - S.E., number of observations shown in 
parentheses. Statistical significance: lv2, 2v3, p< .025; lv3, p< .0025
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Activation of a^-adrenergic receptors causes
formation of two 2nd messengers, IP^ and DAG. IP^
causes an increase in intracellular calcium concentration 
2+([Ca ]^) DAG binds to and activates protein kinase C (PKC),
2+which also requires phospholipid and Ca for maximum 
activation (review: Berridge, 19 87).
Tumour-promoting phorbol esters, such as 12-0-
tetradecanoyl phorbol 13-acetate (TPA), are potent activators
of PKC, mimicking the action of DAG. To determine whether
PKC was the mediator of the a^-induced fall in GPAT activity,
-7
hearts were perfused with 10 M TPA for 5 min. - this is 
known to produce activation of PKC (Yuan et al., 1987).
a) Effect of perfusion with TPA on heart 
performance.
Hearts were perfused normally for 15 min. before
-7
switching to perfusate containing 10 M TPA for 5 min.
Table 3.7 shows that at the end of this perfusion time, 
both heart rate and developed tension are significantly 
reduced, by 17% and 50% respectively. Perfusion pressure 
is increased (by 150%) indicating coronary vasoconstriction. 
These observations are similar to those reported by Yuan 
et al (1987).
b) Effect of perfusion with TPA on activities of 
TGL and GPAT
-7
Hearts were perfused with 10 M TPA for 5 min. before 
removal and homogenization in STEF buffer.
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Table 3.7
-7
Effect of perfusion with 10 M TPA on heart performance
Control TPA
Heart rate
(beats/min)
275 - 37 (9) 229 ± 26 (9)*
Developed tension 
(g/heart)
3.8 ± 0.6 (7) 1.94 - .49 (7)**
Perfusion pressure 
(mmHg)
38.1 - 5.9 (8) 96.3 - 16.9 (8) **
Hearts were perfused normally for 15 min. before switching 
to perfusate containing 10 7M TPA for 5 min. Results are means - S.E.,
number of observations shown in parentheses. Statistical significance:
p< .001, p< .01 v control
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TGL activity does not change in response to TPA 
(Table 3.8). This is consistent with the previous 
observation that a^-agonists do not affect TGL activity.
Table 3.8 shows that whilst GPAT activity in mitochondria 
is unchanged, it is depressed in both crude homogenate 
and microsomal fraction - by 37.5% and 28%, respectively. 
Since the inhibition persists through isolation of the 
microsomal fraction, this suggests that a stable change in 
GPAT activity has occurred.
c) Effect on GPAT activity of incubation of extracts 
of TPA-treated hearts under dephosphorylation conditions
-7
Hearts were perfused with 10 M TPA and homogenized 
in absence of NaF. Extracts were then incubated under 
dephosphorylation conditions as described in 'Methods' to 
determine whether the TPA-induced inhibition of GPAT activity 
could be reversed. Table 3.9 shows that incubation with 
buffer alone produces a partial reactivation of GPAT but 
that full reactivation occurred when the extracts were 
incubated under dephosphorylation conditions.
d) Effect of incubation with TPA on the activities of 
TGL and GPAT
Crude homogenate or supernatant was incubated at 30°C 
-7
for 15 min. with 10 M TPA and the additions shown in 
Table 3.10. These conditions are such as to favour 
activation of protein kinase C (Castagna et al, 1982; see
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Table 3.8
-7
Effect of perfusion with 10 M TPA on the activities 
of TGL and GPAT
Enzyme activity (nmoles/min/mg)
Control TPA
TGL .10 - .01 (5) .105 - .02 (5)
GPAT:
Homogenate .64 - .05 (4) .40 ± .05 (5)*
Mitochondrial fraction .67 - .05 (3) .70 ± .04 (3)
microsomal fraction 4.17 - .26 (4) 3.02 ± .21 (4)*
Hearts were perfused normally for 15 min. before perfusion with
10 M TPA for 5 min. Enzyme activity was measured in the various
subcellular fractions as described in "Methods". Results are means 
+
~ S.E., number of observations shown in parentheses. Statistical
*significance v control: p< .001, other differences not significant .
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Table 3.9
Effect on GPAT activity of incubation of homogenates from 
TPA-treated hearts under dephosphorylation conditions
GPAT activity (nmoles/min/mg)
Initial activity .34 t .05 (3)1
30 min incubation:
buffer only .44 - .07 (5) 2
dephosphorylation
conditions .59 - .07
3
(6)
Hearts were perfused normally for 15 min. without or with perfusion 
with 10 M TPA for 5 min. Homogenates were incubated with buffer 
alone or under dephosphorylation conditions (as described in "Methods") 
for 30 min. at 30°C before measurement of GPAT activity. Statistical 
significance: lv2, NS; 2v3; p< .01; lv3, p< .005
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Table 3.10
-7
Effect of 10 M TPA incubation on heart homogenate enzyme
activities
Enzyme activity (nmoles/min/mg)
TGL GPAT
Initial activity .09 ± .01 (3) .60 + .05 (6)
15 min. incubation with 
buffer only .09 - .02 (6) .60 + .06 (3) 1
ATP .59 + .05 (4)
ATP, PS, Ca2+ .54 + .04 (6)
ATP, TPA .44 + .08 (6) 2
2+ATP, PS, Ca , TPA .09 - .01 (6) .33 + .05 (6) 3
Hearts were perfused normally for 20 min. before incubation of
homogenate (GPAT) or 2000g supernatant (TGL) under the conditions
given for 15 min. at 30°C (as described in "Methods"). Concentrations
2+
used were: 5mM ATP, 20pg/ml phosphatidylserine (PS), lOOyM Ca ,
10 TPA. Results are means - S.E., number of observations shown in
parentheses. Statistical significance: lv2, p< .005; lv3, p< .001;
2v3, p< .025
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'Methods' for details).
Table 3.10 shows that TGL activity is unaffected on 
incubation with TPA, but that GPAT activity is depressed 
by 27%. This is consistent with the observation that 
a^-agonists have no effect on TGL activity but inhibit GPAT 
(Heathers et al 1985). Addition of cofactors of PKC - Ca^+ 
and phosphatidylserine (PS) - caused a further inhibition 
of GPAT, strongly suggesting that PKC activation can 
inhibit GPAT activity.
e) Effect of perfusion with TPA and adrenaline
i) Heart performance
Perfusion of hearts with either adrenaline or TPA
produces different effects on heart function (Table 3.11):
\ _ g
perfusion with 10 M adrenaline for 1 min. increases both
heart rate (not shown) and developed tension whereas
-7
perfusion with 10 M TPA for 5 min. has the opposite effect. 
Perfusion with TPA arid adrenaline together (see 'Methods') 
has the same effect as perfusion with TPA alone, suggesting 
that TPA inhibits the heart's response to adrenaline.
ii) GPAT
GPAT activity was measured in the microsomal fraction 
(see 'Methods'). Perfusion of hearts with either adrenaline 
or TPA produced a decrease in GPAT activity (Table 3.12) - 
by 35% and 30%, respectively. Perfusion with adrenaline and 
TPA simultaneously produced approximately the same decrease 
(35%) in GPAT activity as perfusion with either agent alone.
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Table 3.11
Effect of perfusion with TPA and adrenaline on developed 
tension
Developed tension (g/heart)
Control 4.9 - .97 (12)1
Adrenaline 7.6 - 1.2 (4)2
TPA 1.9 - .50 (4) 3
TPA and adrenaline 2.0 - .40 (3) 4
_ 7 _ r
Hearts were perfused with 10 M TPA and/or 10 M
adrenaline as described on "Methods'1. Results are 
+
means — S.E., number of observations shown in parentheses. 
Statistical significance: all differences p< .001, except
3 v 4 , NS.
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Table 3.12
Effect of perfusion with TPA and adrenaline on microsomal
GPAT activity
GPAT activity (nmoles/min/mg)
Control 4.27 ±
i—
1rooCM•
Adrenaline 2.77 - .23 (4)2
TPA 3.0 - .13 (4)3
TPA and adrenaline 2.72 - .24 (3) 4
_7
Hearts were perfused with 10 M TPA and/or 10 M adrenaline as 
described in "Methods". Hearts were homogenised in buffer 
containing 50mM NaF and GPAT activity measured in a microsomal 
fraction. Results are means — S.E., number of observations shown 
in parentheses. Statistical significance: lv2, p< .001; lv3,
p< .001; lv4 p< .0025. Other differences not significant.
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iii) Phosphorylase
Activation of glycogen phosphorylase 'a' by both
and 8-aarenergic agonists is well documented (review, Hayes,
— 6
1986) . Here, perfusion of hearts with 10 M adrenaline 
increased phosphorylase activity by 100% (Table 3.13).
Perfusion of hearts with TPA also led to a stable 
increase in phosphorylase activity (by 40%; table 313).
This has not been reported previously. Perfusion of 
hearts with adrenaline and TPA together also gave a 40% 
increase in phosphorylase activity - the same result as 
perfusion with TPA alone. This suggests that at the 
concentrations used the TPA effect predominates over the 
adrenaline response.
3.4 Calcium and calcium antagonists
2+The internal calcium concentration ([Ca ]^) of the
myoplasm determines the level of activation of contractile
proteins (review - Hiraoki and Vogel, 1987) which, in turn,
controls the force of developed tension. Changes in 
2+[Ca ] can also alter the activity of a number of other
proteins and enzymes. In particular, glycogen phosphorylase
2+activity is increased (by Ca -induced activation of 
phosphorylase kinase) and that of glycogen synthase 
decreased (review - Hayes, 1986). To determine whether 
the activities of enzymes involved in triglyceride metabolism
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Table 3.13
Effect of perfusion with TPA and adrenaline on phosphorylase
activity
Phosphorylase activity 
(-AMP/+AMP) ratio
Control .15 - .01 (3)1
Adrenaline .32 i .04 (3) 2
TPA .21 - .01 (4) 3
TPA and adrenaline .21 - .01 (3) 4
Hearts were perfused with lo"7M TPA and/or 10_6M adrenaline
as described m  "Methods". Hearts were homogenised in buffer
containing 50mM NaF and phosphorylase activity determined in a
10 OOOg supernatant (after gel filtration - see "Methods"). Results 
+
are means — S.E., number of observations shown in parentheses. 
Statistical significance: lv2, lv3, lv4, p< .01; 2v3, p< .0025;
2v4, p< .05
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2 +are also influenced by Ca , the heart was perfused with
2+ 2+various concentrations of external Ca ([Ca ] ) and also
2+with Ca uptake antagonists.
(Hearts were homogenised in STE buffer and GPAT 
activity measured in crude homogenate in the results 
presented in this section).
a) Effect on heart performance
i) [Ca2+]^
2 +Figure 3.4 shows that as the [Ca ] of the perfusate is
raised from 0.6 to 4.8mM, developed tension increases (heart
rate does not change - results not shown). This result is
2+consistent with the proposal that as [Ca ] is increased,
2+[Ca ] is also increased. As discussed above, this 
increases the activity of contractile proteins.
2 +ii) Ca antagonists
2 +
Ca antagonists bind to the slow calcium channel of
2+the sarcolemma and inhibit Ca entry. The structures of 
diltiazem, nifedipine and verapamil and their properties 
are given in the introduction.
2+The effect of perfusion with Ca antagonists on 
inotropy and chronotropy in the isolated rat heart is shown 
in Table 3.14; hearts were perfused normally for 15 min. 
before switching to perfusate plus antagonist for 5 min.
At the concentrations shown, diltiazem and verapamil produced
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Figure 3.4
24-
Effect of changes in perfusate [Ca ] on developed tension
14
12
10
8
6
4
2
0.
I Ca2 * ]mM
Hearts were perfused (resting tension 2g) with a control [Ca2*] of 1.2mM for 
15 min before the perfusate was switched to [Ca2*] of 0.6, 1.2, 2.4 or 4.8mM 
for 5 min. Results are means ± S.E, number of observations for each value 
=6. Statistical significance v control (1.2mM Ca2*) : 0.6mM Ca2* p<.02;
2.4mM Ca2* p<.02; 4.8mM Ca2" p<.01.
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TABLE 3.14 The effect of Ca2< antagonists on heart rate
and developed tension
Antagonist Developed tension Heart rate
(g/heart) (beats/min)
Control 3.24 ± .38 (18) 208 ± 23 (18)
Diltiazem, 2.05 ± .14 (7) ** 162 ± 19 (7) **
Nifedipine, 10-2M 2.16 ± .21 (6) ** 169 ± 17 (6) *
Verapamil, io~2m 1.72 ± .19 (5) ** 175 ± 10 (5) *
Hearts (resting tension 2g) were perfused normally for 15 min before the 
given concentrations of antagonist were introduced for 5 min. Values are 
expressed as means ± S.E, number of observations (hearts) shown in 
parentheses. Statistical significance v control; * pC.Ol, ** pC.001.
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an approximate 50% decrease in developed tension whereas 
nifedipine had a lesser effect. Heart rate was reduced 
by -20% in each case. Higher concentrations of nifedipine 
(10 ^M) and verapamil (10 ^M) reduced developed tension to 
zero and produced very low heart rates (results not shown).
b) Effect on TGL and GPAT activities
2+
i) jCaT_J_0
2+Hearts were perfused with [Ca ]q of 0.6 to 4.8mM.
2+TGL activity is reduced by 40% at [Ca ] of 0.6mM (Table 
3.15) compared to the control value at 1.2mM. At 
concentrations above the control value, no further increase 
in TGL activity occurs. GPAT activity is strongly inhibited 
(>50%) at [Ca^+]Q above 1.2mM; at 0.6mM Ca^+ , a slight but 
significant activation occurs.
2 +ii) Ca antagonists
2+All three Ca antagonists inhibited TGL activity 
(Table 3.16); diltiazem and nifedipine produced an 
approximate 25% decrease in activity whereas verapamil 
causes a 45% decrease. Since both developed tension and 
heart rate are reduced in presence of these antagonists, 
the reduced TGL activity may reflect a reduced energy demand 
by the heart. Diltiazem and verapamil produce a significant 
increase in GPAT activity (Table 3.16)whereas the slight 
activation produced by nifedipine does not reach statistical 
significance.
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TABLE 3.15 The effect on enzyme activity of changes
in perfusate [Ca2*]
TGL activity GPAT activity
(nmoles/min/mg)
0. 6mM Ca2* .06 ± .01 (4) **★
00 ± .05 (4) *
1.2mM Ca2" .10 ± .02 (5) .57 ± .07 (6)
2.4mM Ca2 * .09 ± .01 (6) .29 ± .02 (6) **
£» 00 Ca2* .10 ± .02 (6) .24 ± .06 (6) **
Hearts were perfused normally for 15 min before being switched to perfusate 
containing the given [Ca2 *] for 5 min. At this time hearts were removed and 
enzyme activities determined. Values are expressed as means ± S.E., number 
of observations shown in parentheses. Statistical significance v 1.2mM Ca24 
* p<.05, ** p<.005, *** p<.001.
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TABLE 3.16 The effect on enzyme activity of Ca2 + antagonists
TGL activity GPAT activity 
(nmoles/min/mg)
Control .10 ± .01 (6) .58 ± .06 (6)
Diltiazem, 10_eM .08 ± .01 (6) *** .67 ± .06 (6) *
Nifedipine, 10“’7M .08 ± .01 (6) *** . 64 ± .07 (6)
Verapamil, 10" 7M .06 ± .01 (5) **** .78 ± .11 (6) **
Hearts were perfused normally for 15 min before the Ca2+ antagonist was 
introduced into the perfusate at the given concentration for 5 min. At this 
time hearts were removed and enzyme activities determined. Values are 
expressed as means ± S.E., number of observations shown in parentheses. 
Statistical significance v relevant control: * p<.05, ** p<.01, *** p<.005, 
**** pc.OOl.
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c) Effect of preperfusion with diltiazem on enzyme
activity during ischaemia and reperfusion
2 +[Ca ]^ is known to increase during ischaemia and
reperfusion (Jennings et al., 1985). To determine whether 
2 +blockage of Ca entry during ischaemia and reperfusion would 
alter enzyme activity, diltiazem was introduced into the 
perfusate 5 min. before induction of ischaemia and remained 
present throughout ischaemia and reperfusion.
Induction of regional ischaemia for 10 min. leads to a 
50% increase in TGL activity (Table 3.17) which is restored 
to pre-ischaemic values on reperfusion. This agrees with 
previous work from this laboratory (Heathers arid Brunt, 1985). 
Although perfusion with diltiazem decreased TGL activity 
initially (Table 3.17), the same degree of activation of 
TGL occurs during iscnaemia of diltiazem-treated hearts 
as occurs in control hearts. On reperfusion, TGL activity 
is again restored to pre-ischaemic values. Thus diltiazem 
does not affect the ischaemia-induced increase in TGL activity.
Compared with the non-ischaemic area, GPAT activity is
reduced by 30% in the ischaemic area of control hearts
(Table 3.18). On reperfusion, GPAT activity is further
reduced to approximately 50% of the pre-ischaemic value.
Perfusion with diltiazem does not alter the ischaemia-
induced fall in GPAT activity. However, on reperfusion
of hearts perfused with diltiazem, GPAT activity returned
2+to pre-ischaemic values, i.e. blockage of Ca entry on
TABLE 3.17
The effect on TGL activity of perfusion with diltiazem 
during ischaemia and reperfusion
TGL activity (nmoles/min/mg)
Control hearts Diltiazem-treated hearts
NI I NI I
10 min ischaemia .11 ± .01 (6) .16 ± .001 (6)* .05 ± .01(7) .08 ± .01(7)
10 min ischaemia +
5 min reperfusion .10 ± .01(6) .10 + .01(6) .06 ± .01(6) . 06±.01(8)
Control and diltiazem-perfused hearts were subjected to 10 min regional ischaemia with or without 5 
min reperfusion. Tissue samples were taken from the non-ischaemic (NI) and ischaemic (I) areas and 
TGL activity determined as detailed in 'Methods and Materials'. Values are expressed as means ±
S .E ., number of observations shown in parentheses. Statistical significance for ischaemic v non- 
ischaemic areas: *p<.001.
TABLE 3.18 The effect on GPAT activity of perfusion 
with diltiazem during ischaemia and reperfusion
Control hearts
GPAT activity (nmoles/min/mg) 
Diltiazem-treated hearts
NI I NI I
10 min ischaemia .64 ± .10 (6) .45 ± .05 (6)* .74 ± .04 (7) .51 ± .06 (7)*
10 min ischaemia +
5 min reperfusion .67 ± .13 (6) .34 ± .11 (6)* .64 ± .06 (8) .67 ± .09 (8)
Control and diltiazem perfused hearts were subjected to 10 min regional ischaemia with or without 5 
min reperfusion. Tissue samples were taken from the non-ischaemic (NI) and ischaemic (I) areas and 
GPAT activity determined as described in 'methods and materials'. Values are expressed as means ± 
S.E., number of observations shown in parentheses. Statistical significance for ischaemic v non- 
ischaemic areas:*p<.001.
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reperfusion prevented the reperfusion-induced decrease 
in GPAT activity.
2 +d) Effect of Ca in the GPAT assay buffer
2+The above results suggest that increases in [Ca
can inhibit GPAT activity. To determine whether this was
2+a direct effect of Ca or whether another mediator, such as 
2+a Ca -dependent protein kinase., was involved, the GPAT
2+assay was performed using buffers of known [Ca ] (see 
"Methods" for preparation of these buffers).
24-Table 3.19 shows that [Ca ] of 10 - 100 yM has no
2+effect on GPAT activity. The free [Ca of the myoplasm
is normally in the range 0.1 to 10 yM (Marban et al.,1980).
2+Therefore, it appears that Ca does not directly inhibit
GPAT but must be working via another mediator, such as a 
2+Ca -dependent protein kinase.
3.5 The Diabetic Heart
Rats were made diabetic by a single injection of 
streptozotocin and hearts isolated 2 days later, as 
described in "Methods". This model of diabetes has been 
reported to produce elevated blood levels of glucose and 
ketone bodies (Jenkins, 1986) .
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Table 3.19
Effect on GPAT activity of Ca2+ in the assav buffer
[Ca2+] (yM) GPAT activity (nmoles/min/mg)
10 .64 - .06 (5)
50 .61 - .09 (5)
100 .61 - .06 (5)
GPAT activity was measured in homogenates of perfused hearts.
2+
Assay buffer of known [Ca } were prepared as described in "Methods". 
Results are means - S.E., number of observations shown in parentheses. 
There are no statistically significant differences.
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GPAT activity in this section was measured in the 
microsomal pellet. For ischaemic studies, hearts were 
made globally ischaemic as it was difficult to obtain 
enough material from the regionally ischaemic model to 
measure GPAT activity in a microsomal fraction. Hearts 
were homogenized in buffer containing 5QmM NaF.
Diabetes causes increased circulating levels of free 
fatty acids which are responsible for the increased triglyceride 
content of the diabetic heart (Feuvray et al 19 79). However, 
in these experiments hearts were perfused with normal concentra­
tions of glucose in order to make a direct comparison with 
results obtained from hearts of normal rats.
a) Heart performance
After 20 min. of normal perfusion, heart function is 
depressed in this model of diabetes; heart rate by 30% and 
developed tension by 25% (Table 3.20).
b) Enzyme activity during ischaemia and reperfusion
i) TGL
Following 20 min. normal perfusion, basal TGL activity 
is depressed by 60% in diabetic hearts compared with normals 
(Table 3.21). Induction of 10 min. ischaemia causes a 50% 
activation of TGL in normal hearts, whereas a 100% activation 
occurs in hearts from diabetic rats.
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Table 3.20
Effect of diabetes on heart function
Heart rate Developed tension
(beats/min) (g/heart)
Control 286 i 30 (9) 5.2 - 1.0 (9)
Diabetic
4-  ★  *
203 - 19 (7) 3.9 - .50 (7)*
Hearts from normal and diabetic rats were perfused for 30 min.
with a resting tension of 2g as described in "Methods". Results 
+
are means - S.E., number of observations shown in parentheses. 
Statistical significance v control: p< .005, p< .001
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Table 3.21
Effect of ischaemia on TGL activity in hearts from
normal and diabetic rats
TGL activity (nmoles/min/mg)
Normal Diabetic
Control .11
i—
1VO1—1 
o+ i .04 ± .007 (4)3
10 min ischaemia .16 + 7-  .o i  ( 6 r .07 - .02 (4)4
Hearts from normal and diabetic rats were perfused normally for 
10 min. before induction of 10 min ischaemia, as described in 
"Methods"; TGL activity was determined in the 2000g supernatant. 
Results are means - S.E., number of observations shown in parentheses. 
Statistical significance: lv2, lv3, 2v4, 3v4, p< .001
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ii) CATj.
The diabetic heart contains elevated levels of long 
chain acyl carnitine (LCAC) (Feuvray et al 1979) and 
inhibition of LCAC formation has been reported to improve 
performance of diabetic hearts (Rosen et al 1986). We 
therefore studied the activity of the enzyme responsible 
for LCAC formation, namely, CAT^.. Table 3.22 shows that 
CAT^ activity is unchanged in perfused hearts from diabetic 
rats. Also, neither induction of 10 min. ischaemia nor 
1 min. reperfusion caused any significant changes in CAT^ 
activity in hearts from either normal or diabetic rats.
iii) GPAT
Basal microsomal GPAT activity is slightly, but 
significantly, depressed in perfused hearts from diabetic 
rats (Table 3.23). Induction of 10 min. global ischaemia 
produces a similar decrease in GPAT activity in both normal 
and diabetic hearts - 35% and 27% respectively. 1 min. 
reperfusion led to a further depression in GPAT activity in 
normal hearts. However, on reperfusion of diabetic hearts 
no further significant decrease in GPAT activity occurred.
iv) Phosphorylase
Basal phosphorylase activity is elevated by 70% in this 
model of diabetes (Table 3.24). Induction of ischaemia in 
normal hearts causes a 33% activation of phosphorylase, 
whereas a smaller activation occurs during ischaemia of 
diabetic hearts (17%). On reperfusion of normal hearts, a
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Table 3.22
Effect of ischaemia and reperfusion on CAT  ^ activity
in hearts from normal and diabetic rats
CAT^ activity (nmoles/min/mg)
Normal Diabetic
Control 5.37 - .61 (4) 5.67 - .83 (5)
10 min ischaemia 5.58 ± .47 (4) 5.41 ± .41 (3)
10 min ischaemia & 
1 min reperfusion 5.41 - .29 (3) 5.25 i .92 (4)
Hearts from normal and diabetic rats were perfused for 10 min. 
before induction of 10 min ischaemia without or with 1 min 
reperfusion, as described in "Methods”. CAT^ . activity was measured
in the mitochondrial fraction (10 OOOg pellet). Results are
+ , 
means - S.E., number of observations shown in parentheses. There
are no statistically significant differences (i.e. p> .05) between
any of the groups .
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Table 3.23
Effect of ischaemia and reperfusion on microsomal GPAT
activity in hearts from normal and diabetic rats
GPAT activity (nmoles/min/mg)
Normal Diabetic
Control 4.27 - .20 (3)1 3.17 - .27
4nr
10 min ischaemia 2.81 - .39 (5) 2 2.38 - .33 (3) 5
10 min ischaemia and
1 min reperfusion 2.18 ± .31 or 2.09 - .41 (3)b
Hearts from normal and diabetic rats were perfused normally for 
10 min. before induction of 10 min. ischaemia with or without 1 min. 
reperfusion, as described in '*Methodsn. Control hearts were perfused 
normally for 20 min. GPAT activity was measured in the microsomal 
fraction (200 OOOg pellet). Results are means - S.E., number of 
observations shown in parentheses. Statistical significance: 
lv2, p< .001-; lv3, p< .001; 2v3, p< .05; 4v5, p< .05; 4v6, p< .025;
lv4, p< .005; other differences not significant.
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Table 3.24
Effect of ischaemia and reperfusion on phosphorylase
activity in hearts from normal and diabetic rats
Phosphorylase activity (-AMP/+AMP) ratio
Normal Diabetic
Control .15 - .01 (3) .24 + 4 - .025 (3)
10 min ischaemia .20 - .03 (3)2 .28 + 5 - .01 (3)^
10 min ischaemia and 
1 min reperfusion .26 ± .04 (5)3 .30 - .06 (3)6
Hearts from normal and diabetic rats were perfused for 10 min 
before induction of 10 min. ischaemia without or with 1 min. 
reperfusion. Control hearts were perfused for 20 min. Phosphorylase 
activity was determined in the 10 OOOg supernatant following gel 
filtration, as described in "Methods". Results are means - S.E., 
number of observations shown in parentheses. Statistical 
significance: lv2, p< .025; lv3, p< .0025; 2v3, p< .05; 4v5, p< .05;
lv4, p< .0025; 2v5, p< .01 Other differences not significant.
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further significant activation of phosphorylase occurs 
beyond that seen during ischaemia. However, on reperfusion 
of diabetic hearts there was no further increase in 
phosphorylase activity.
c) Effect of adrenaline on enzyme activity
Hearts from both normal and diabetic rats were perfused 
for 20 min. before exposure to 10 M adrenaline for 1 min. 
as described in "Methods".
i) TGL
— 610 M adrenaline produces a 50% rise in TGL activity in 
normal hearts (Table 3.25). Basal TGL activity is 
depressed in diabetic hearts, but perfusion with adrenaline 
induces a 100% rise in activity.
ii) CATI
The activity of this enzyme is not under the direct
control of adrenergic hormones i.e. does not undergo
phosphorylation. This is shown here in Table 3.26, where
there is no change in CAT^ activity following perfusion with 
610 M adrenaline in hearts from either normal or diabetic 
rats.
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Table 3.25
Effect of perfusion with adrenaline on TGL activity in
hearts from normal and diabetic hearts
TGL activity (nmoles/min/mg)
Normal Diabetic
Control .10 - .01 (6) 1 .04 - .005 (7) 3
10 M adrenaline .15 - .02 (6) 2 .08 - .015 (6) 4
Hearts from normal and diabetic rats were perfused for 20 min.
“ 6without (control) or with 10 M adrenaline for 1 min. TGL 
activity was determined in a 2000g supernatant, as described in 
"Methods". Results are means — S.E., number of observations 
shown in parentheses. Statistical significance: lv2, lv3, 3v4,
2v4, p< .001
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Table 3.26
Effect of perfusion with adrenaline on CAT .^ activity in
hearts from normal and diabetic rats
CAT^ activity (nmoles/min/mg)
Normal Diabetic
Control 5.37 - .61 (4) 5.84 - .42 (3)
"" 610 M adrenaline 5.57 - .83 (5) 5.09 i .59 (3)
Hearts from normal and diabetic rats were perfused for 20 min.
_6
without (control) or with exposure to 10 M adrenaline for 1 min. as 
described in "Methods". CAT^ . activity was measured in the mitochondrial 
fraction (10 OOOg pellet). Results are means - S.E., number of 
observations shown in parentheses. There are no statistically 
significant differences between any of the groups.
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iii) GPAT
"" 6In normal hearts, exposure to 10 M adrenaline 
caused a 35% decrease in GPAT activity measured in the 
microsomal fraction. In diabetic hearts, the depressed 
basal GPAT activity is further inhibited by adrenaline 
(A 35% decrease in activity), (Table 3.27).
iv) Phosphorylase
Activation (phosphorylase by adrenaline is well
““ 6known. Here, perfusion with 10 M adrenaline caused a 
100% activation of phosphorylase in normal hearts 
(Table 3.28). Basal phosphorylase activity is increased 
in diabetes but adrenaline produces a further 100% increase 
in activity (Table 3.28) .
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Table 3.27
Effect of perfusion with adrenaline on microsomal GPAT
activity in hearts from normal and diabetic rats.
GPAT activity (nmoles/min/mg)
Normal Diabetic
Control 4.47 ± .20 (3)1 3.32 i .28 (3) 3
— 6
10 M adrenaline 2.77 i- .23 2(4) 2.16 i .35 (3) 4
Hearts from normal and diabetic rats were perfused for 20 min.
_6
without (control) or with exposure to 10 M adrenaline for 1 min. 
GPAT activity was determined in the microsomal fraction (200 OOOg 
pellet). Results are means — S.E., number of observations shown 
in parentheses. Statistical significance: lv2, p< .001; lv3,
p< .005; 3v4, p< .025; 2v4, p< .05
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Table 3.28
Effect of perfusion with adrenaline on phosphorylase
activity in hearts from normal and dia.betic rats
Phosphorylase activity(-AMP/+AMP) ratic
Normal Diabetic
Control .15 - .006 (3)1 .24 - .014
3
(3) J
*” 610 M adrenaline .32 - .035
2
(4r .51 - .066
4
(3P
Hearts from normal and diabetic rats were perfused for 20 min.
_6
without (control) or with exposure to 10 M adrenaline for 1 min. 
Phosphorylase activity was determined in a 10 OOOg supernatant after 
gel filtration, as described in "Methods”. Results are means - S.E., 
number of observations shown in parentheses. Statistical 
significance: lv3, p< .0025; lv2, p< .01; 3v4, p< .01; 2v4, p< .05.
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4.1 Adrenergic effects on the activities of triglyceride
lipase and glycerol 3-phosphate acyltransferase
a) Triglyceride lipase
In the heart, hydrolysis of endogenous triglyceride is 
under acute hormonal control (Severson, 1979): perfusing
the isolated rat heart with catecholamines increases glycerol 
output and reduces the level of myocardial triglyceride 
(Crass et al., 1975). Triglyceride lipase (TGL) catalyses 
the initial, rate limiting step in triglyceride hydrolysis 
(StanL et al., 1986) however, the nature of TGL has been 
controversial: a residual form of lipoprotein lipase
(Hulsmann et al., 1982; Palmer and Kane, 1983) versus a 
distinct neutral lipase (Goldberg and Khoo, 19 85; Ramirez 
et al., 1985). Most recent evidence is in favour of the 
latter (Holm et al., 1988; Small et al., 1989) and the assay 
employed here to determine TGL activity was designed to 
distinguish between it and LPL (Al-Muhtaseb, 1983).
In adipose tissue, the existence of a neutral triglyceride 
lipase has been known for some time and it has been termed 
hormone-sensitive lipase since it is phosphorylated and 
activated in response to catecholamines (Belfrage et al.,
1977). Recently, the gene for hormone sensitive lipase has 
been cloned from rat adipocytes (Holm et al., 1988); the 
predicted amino acid sequence showed no homology with that 
of lipoprotein lipase, despite similar functions of the lipases, 
and RNA blot analysis revealed that the gene for hormone 
sensitive lipase was also present in rat heart.
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Thus the existence of neutral TGL in heart muscle is 
now well established and it is also agreed that its activity 
can be stimulated by catecholamines (Heathers et al., 1985;
Table 3.3, this thesis, Severson et al., 19 80). However, 
whether a direct phosphorylation of the enzyme by cAMP-PrK 
occurs (as in adipose tissue) has again been controversial.
TGL activity was found to increase on incubation of rat 
(Heathers et al., 1985) and mouse (Goldberg and Khoo, 1985) 
heart extracts with cAMP, ATP and cAMP-PrK. A similar result 
was obtained by Schoonderwoerd et al., (1987) using rat heart,
but these workers suggested that the increase in TGL activity 
was not due to phosphorylation of the enzyme. Instead, they 
suggested that TGL activity was increased as a result of 
removal of inhibitory fatty acids from the catalytic site of 
the enzyme by re-esterification: cAMP-dependent phosphorylation
of phosphorylase leads to a stimulation of glycogenolysis 
thereby increasing the supply of glycerol 3-phosphate. This 
latter would then react with fatty acids to re-form triglyceride 
However, our observation that myocardial GPAT activity is 
decreased on incubation of heart extracts with cAMP-PrK 
(Heathers et al., 1985; Figures 3.2 and 3.3, this thesis) 
does not support this hypothesis - a depressed GPAT activity 
would inhibit re-esterification of fatty acids. Also, Palmer 
et al., (1987) observed the increase in TGL activity with 
cAMP-PrK even when their assay system was depleted of glycogen. 
Recently, evidence for direct phosphorylation of myocardial 
TGL was provided by Small et al., (19 89): incubation of rat
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heart extracts with cAMP-PrK and (y P)ATP caused 
phosphorylation of an 84K polypeptide which could be 
precipitated by antiserum raised against purified hormone- 
sensitive lipase from adipose tissue. The experiment was 
repeated using isolated myocytes to exclude the possibility 
that TGL was derived from intramuscular adipocytes or other 
cell types.
Thus most recent evidence is strongly in favour of a 
distinct TGL in heart muscle which is phosphorylated and 
activated by cAMP-PrK upon catecholamine-induced stimulation 
of the heart.
B-adrenergic agonists only are effective in stimulating 
TGL, perfusion of isolated rat hearts with a-^-agonists had 
no effect on TGL activity (Heathers et al., 1985). TGL 
activity is inhibited by high concentrations of free fatty 
acid and fatty acyl CoA (Severson, 1979; Al-Muhtaseb, 1982) 
but whether this inhibition would overcome the activation 
produced by phosphorylation is not known and requires further 
investigation.
b) Glycerol 3-phosphate acyltransferase
Most work outside this laboratory has focussed on 
glycerol 3-phosphate acyltransferase (GPAT) of adipose 
tissue (Nimmo, 1984; Rider and Saggerson, 1983). There is 
no conclusive evidence as to whether the adipose tissue 
enzyme is under acute hormonal control: Rider and Saggerson
(1983) observed a stable decrease in microsomal, but not 
mitochondrial, GPAT activity in response to incubation of
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rat adipocytes with noradrenaline; however, no change in
activity was found when untreated adipocytes were incubated
with cAMP-PrK. This is in contrast to results obtained by
Nimmo (19 80; 1981) who found that GPAT activity was
depressed on incubation of a microsomal fraction from rat
adipocytes with cAMP-PrK. Initially, this was suggested
to be due to cAMPrdependent phosphorylation of GPAT, but in
a later paper (Nimmo and Nimmo, 1984) the band phosphorylated 
32with (y P )ATP (upon SDS-PAGE of adipocyte microsomes
32incubated with (y P)ATP and the catalytic subunit of 
cAMP-PrK) was found to differ in molecular weight by 
500-1000 from that thought to be GPAT (54K). No alternative 
mechanism for the cAMP-induced inhibition of GPAT was proposed. 
A recent paper by Walsh et al., (1989) found adipocyte 
microsomal GPAT was inhibited on incubation with ATP alone, 
and that no further inhibition occurred on adding cAMP-PrK, 
suggesting that a cAMP-independent phosphorylation was 
involved.
Previous work from this laboratory found a decrease in 
myocardial GPAT activity in crude homogenate following 
perfusion of isolated rat hearts with adrenaline (Heathers 
et al., 19 85). The present study confirms this observation - 
GPAT activity was depressed by 38% in response to adrenaline 
(Table 3.3) and further shows that, upon isolation of 
subcellular fractions, mitochondrial GPAT activity was 
unchanged but that of the microsomal fraction depressed by 
16% (which was statistically significant). Since GPAT 
activity in homogenate was inhibited by nearly 40%, this
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suggested that a re-activation of GPAT occurred during 
isolation of the microsomal fraction (which took approximately 
1 hr. following removal of the heart from the perfusion 
apparatus). If GPAT is indeed phosphorylated by adrenaline, 
it is possible that the reactivation was due to the action of 
endogenous phosphoprotein phosphatases. To determine 
whether this was the case, following perfusion (without or 
with adrenaline) the heart was homogenised in buffer 
containing 50mM NaF (a phosphatase inhibitor). There was 
no further inhibition of GPAT in crude homogenate (Table 3.4) 
but activity in the microsomal fraction was depressed by 
36%, suggesting that phosphatase action was indeed responsible 
for the reactivation of GPAT. This is further evidence 
that GPAT is phosphorylated and inactivated in response to 
adrenaline.
Rider and Saggerson (19 83) observed a large decrease in 
microsomal GPAT activity on incubation of rat adipocytes with 
noradrenaline, NaF had no effect on this decrease, however, 
if albumin was included in the homogenization buffer, the 
noradrenaline-induced inhibition was abolished. No 
explanation was given for the effect of albumin. The 
effect of albumin on myocardial GPAT inactivation has not 
been studied. However, it may be that different mechanisms 
operate for the control of GPAT in heart and adipose tissue: 
Specific GPAT activity is approximately ten times higher in 
adipose tissue where the concentrations of triglyceride and 
fatty acid metabolites would be much higher than in heart
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muscle. It is possible that such metabolites have an 
important role in regulating adipose tissue GPAT activity 
whereas in heart the main control mechanism is by 
phosphorylation. The susceptibility of the dephosphorylated 
and phosphorylated forms of the enzyme to control by factors 
such as fatty acids and metabolites needs to be investigated.
The depression in myocardial GPAT activity (in crude 
homogenate) produced by adrenaline can be reversed on 
incubation of homogenates under dephosphorylation conditions 
(Heathers et al. , 1985; Table 3.5). Incubation of both 
homogenate and microsomal fraction of untreated hearts with 
cAMP-PrK also produces a decrease in GPAT activity (Figures
3.2 and 3.3).
Perfusion of isolated rat hearts with both and 8- 
adrenergic agonists can inhibit GPAT (Heathers et al., 1985). 
Whereas the results of this study and previous work show 
that the 8-receptor mediated inhibition may be due to cAMP- 
dependent phosphorylation of GPAT, the mechanism of a^-induced 
inhibition was not known. Investigation of this has been the 
subject of much of the work of this thesis and is discussed 
in Sections 4.3 and 4.4.
From the results of this section it can be concluded 
that when the heart is challenged by an adrenergic stimulus, 
endogenous triglycerides are mobilized by activation of TGL 
whilst at the same time wasteful recycling of fatty acids is 
depressed by inhibition of GPAT activity. In absence of the 
hormonal stimulus, the activities of these enzymes may be 
governed by the supply of substrates.
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4.2. Ischaemia and reperfusion-induced changes in
enzyme activity
The levels of free fatty acid, fatty acyl CoA and 
acylcarnitine rise during ischaemia (Feuvray et al., 1979). 
However, only after long (>1 hour) periods of ischaemia could 
a change in the level of triglyceride or phospholipid be 
observed in the ischaemic heart (van Bilsen et al., 1989).
It has been suggested that these conflicting results arise from 
the fact that current assay methods are not sensitive enough 
to measure small changes in triglyceride levels (van Bilsen 
et al., 1989). Thus a 5% decrease in triglyceride levels 
(which might be disregarded as being insignificant) can 
provide a 5-fold increase in fatty acid levels. The increase 
in fatty acids and metabolites occurring during ischaemia has 
been associated with cell damage and implicated in the genesis 
of ischaemia-induced arrhythmias (Corr et al., 19 84). Altered
control of lipid metabolism is thus an important area of 
investigation for the ischaemic myocardium.
An increased release of endogenous noradrenaline occurs 
in the ischaemic myocardium, as discussed in more detail in 
the 'Introduction'. This has also been implicated in 
arrhythmogenesis since blockage of both a and 8 - a d r e n e r g i c  
receptors is beneficial in protecting against ischaemia and 
reperfusion-induced arrhythmias.
Previous work has shown that, on induction of regional
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ischaemia in the isolated perfused rat heart, a rise in 
TGL activity and a fall in GPAT activity occurred in the 
ischaemic area (Heathers and Brunt, 19 85). This has been 
confirmed in the present study (Tables 3.17 and 3.18). 
Preperfusion of the heart with 6-, but not a^-adrenergic 
antagonists prevented these changes in enzyme activity 
suggesting an increased B-adrenergic activity during 
ischaemia. Other workers have provided evidence for an 
increase in the actual number of 8-receptors in ischaemic 
tissue (Maisel et al., 1987). On reperfusion of the 
previously ischaemic area, TGL activity returned to control 
pre-ischaemic values, but GPAT activity was further 
depressed (Heathers and Brunt, 1985). This reperfusion- 
induced fall in GP^T activity was prevented by a - but not 
8 -antagonists, suggesting that, on reperfusion, B-adrenergic 
activity returns to normal but an a^- drive becomes apparent. 
Other workers have also observed an increase in a^-activity 
on reperfusion of the myocardium - this has been described 
in Section 1.
The work in this study has confirmed the changes in 
TGL and GPAT activity occurring upon induction of regional 
ischaemia, and also show that similar changes occur when the 
globally ischaemic model is used. Using this model it was 
possible to obtain enough tissue to measure GPAT activity in 
the microsomal pellet. Phosphorylase activity in the 10 OOOg
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supernatant of the same tissue was also measured. Control 
of phosphorylase activity by both a-^  and 3■'■adrenergic 
mechanisms is well known (review Hayes, 19 86) and it was 
therefore desirable to compare changes in phosphorylase 
activity with changes in GPAT activity. NaF was included 
in the homogenisation buffer to prevent the action of 
phosphatases on the enzymes.
After 10 min. global ischaemia, microsomal GPAT activity 
was found to decrease by 35%, and phosphorylase activity to 
increase by 35% (Tables 3.23 and 3.24). On reperfusion for 
1 min., a further depression of GPAT activity and a further 
elevation of phosphorylase activity occurred. Both these 
changes in activity were very stable. Thus isolation of 
the microsomal pellet took approximately 1 h. following 
removal of the heart from the perfusion apparatus and 
phosphorylase activity was assayed after gel filtration of 
the 10 OOOg supernatant. Thus phosphorylation of the 
enzymes seems the most likely explanation for the observed 
changes in activity. The reperfusion-induced fall in GPAT 
activity can be prevented by a^-antagonists in the regionally 
ischaemic model. It would be interesting to determine 
whether preperfusion of the heart with adrenergic antagonists 
prevents the ischaemia and reperfusion-induced changes in 
phosphorylase activity as has been found with the GPAT 
activity. Further work needs to be carried out to determine 
whether the changes in GPAT, TGL and phosphorylase activities
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during ischaemia can be correlated with changes in cAMP
levels and cAMP-PrK activity. If a^-activity is indeed
responsible for the reperfusion-induced changes in GPAT and
phosphorylase activities, the mechanism of the changes will
need to be established. a^-Activation produces an increase 
2 +in [Ca and activates protein kinase C (PKC). It has
2+been shown that an increase in [Ca occurs during
reperfusion of the myocardium (Shen and Jennings, 1972).
The influence of such an increase on GPAT activity is discussed 
in Section 4.3. Whether PKC activation can alter the 
activities of GPAT and phosphorylase is discussed in 
Section 4.4. It would be of great interest to determine 
the changes in PKC activity occurring during ischaemia and 
reperfusion of the heart.
4.3. Calcium and calcium antagonists.
Stimulation of a^-receptors causes both an increase 
2+in [Ca ] ^  and an activation of protein kinase C (PKC).
A possible mediator of the a^-induced fall in GPAT activity
2+ 2+is an increase in [Ca 1^. [Ca increases during
reperfusion of the myocardium (Shen and Jennings, 1972) when, 
as we have shown, there is a decrease in GPAT activity.
This reperfusion-induced decrease in GPAT activity can be 
prevented by pre-perfusing the heart with a^-antagonists 
(Heathers and Brunt, 19 85) and evidence for such 
intensification of a^-activity during reperfusion has been 
found elsewhere (Stewart et al., 1980; Sharma et al., 1983).
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a) Effect on enzyme activity
2+To determine whether alterations in [Ca ]. would
1
alter enzyme activity, hearts were perfused with various
2+ 2+[Ca ]q (0.6 - 4.8mM) and with the Ca antagonists
diltiazem,nifedipine and verapamil. These all act by
2+ 2+ inhibiting the Ca channel and thus reducing Ca entry
2+into the myocardium. Increasing [Ca ]q increased
2+developed tension. This result suggests that [Ca ] was
increased which led to an activation of contractile proteins.
2+All three Ca antagonists reduced both heart rate and
developed tension (Table 3.14). This well established
property (review Fleckenstein, 19 84) has been suggested to
account, at least in part, for the anti-arrhythmic action of 
2+Ca antagonists. Here the results obtained (Table 3.16)
2+show that TGL activity is inhibited by both Ca antagonists 
2 +and by low [Ca ] (0.6mM). The activity appears maximal at
2+ 2+1.2mM [Ca ] . The responsiveness of TGL to Ca requires
further investigation which would involve purification of
2+myocardial TGL and accurate estimations of [Ca ]^.
GPAT activity is strongly inhibited in response to
24-
high [Ca ] whereas, compared to control values at 1.2mM
2+ 2+ 2+(Ca ) , either low [Ca ]q or Ca antagonists produce an
increase in activity.
2+The enzyme activities at high [Ca ] are similar to
those found on reperfusion of the isolated ischaemic rat heart, 
2 +when [Ca is known to increase (review, Jennings et al.,
1985).
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b) Effect of pre-perfusion with diltiazem on enzyme
activity during ischaemia and reperfusion
2+ 2+During reperfusion [Ca ]  ^ is raised by Ca influx
2+from outside the cell. The Ca entry mechanisms are not
2 +fully understood but may involve a stimulation of Ca slow
channels by (1) catecholamine-induced phosphorylation
(2) palmitoyl carnitine accumulation (Mir and Spedding,
1986) or (3) a^-stimulated Ca^+ influx (Sharmaet al., 1983). 
2+If Ca antagonists prevent the reperfusion induced increase
2+ 2+ in [Ca ]^, alterations in Ca -sensitive enzyme activity
might be expected. Inclusion of diltiazem in the perfusate
prior to induction of regional ischaemia caused an inhibition
of TGL activity in both non-ischaemic and ischaemic tissue
(Table 3.17) . This effect was similar to that seen with low 
2+[Ca ] and suggests that the treatment was successful in 
2+limiting Ca influx. The extent of TGL stimulation 
caused by ischaemia in the presence of diltiazem was 
identical to that seen in its absence. This suggests 
that such ischaemic effects are entirely 6-mediated as has 
been argued earlier.
On reperfusion, diltiazem did not influence the return 
of TGL activity to pre-ischaemic values. It did not 
prevent the ischaemia-induced inhibition of GPAT activity 
(Table 3.18). However, pre-perfusion with diltiazem did 
prevent the reperfusion-induced fall in GPAT activity.
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A similar result had been obtained with the a^-antagonist
doxazosin (Heathers and Brunt, 1985). Thus this result
2+suggests that the a^-induced effect was caused by Ca
entry on reperfusion which inhibited GPAT. It is unlikely 
2+that Ca directly inhibits GPAT since the inclusion of 
2+10-lOOyM Ca in the GPAT assay buffer had no effect on
2+
activity (Table 3.19). It is possible that Ca entry on
2+reperfusion activates a Ca -dependent protein kinase which 
via phosphorylation inhibited GPAT activity.
Thus under control conditions it is suggested that the
reperfusion-induced fall in GPAT activity would delay removal
of (3-adrenergically generated fatty acids or their metabolites
accumulating during ischaemia (Corr et al., 1984), and that
this would delay the recovery of heart performance.
Diltiazem prevents the reperfusion-induced fall in GPAT
2+activity and provides another mechanism whereby Ca 
antagonists protect against reperfusion-induced injury 
of the myocardium.
4.4. Effects of phorbol esters (protein kinase C activation)
Stimulation of the heart with a^-adrenergic agonists
results in the formation of two 2nd messengers - IP^ which
2+causes an increase in [Ca ]^, and diacylglycerol (DAG),
which activates protein kinase C (PKC) (review - Berridge, 1987)
2+The effect of changes in [Ca ] on enzyme activity has been 
discussed in Section 4.3. The experiments discussed in 
this section were designed to investigate the effects on
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enzyme activity of the other half of the a^-signalling 
pathway, namely PKC activation. For this reason, phorbol 
esters, which are potent activators of PKC (Castagna et al., 
1982), were used.
Phorbol esters have a similar structure to that of DAG
and activate PKC directly both in vivo and in vitro (Niedel
2+et al., 1983). PKC requires Ca and phospholipid
(particularly phosphatidyl-serine) for activity (review,
Nishizuka, 1986); phorbol esters and DAG increase the
2+activity of PKC even at maximal Ca concentrations. More
2+importantly they decrease the concentration of Ca required 
for half maximal activity. This is reduced to the 
submicromolar range found in the cytosol (Exton, 19 88). A 
major difference between phorbol esters and DAG is that 
whereas DAG is present for only a short time following cell 
stimulation, phorbol esters are hardly degraded by the cell 
and so may prolong the activation of PKC. This may distort 
the normal sequence of events. Therefore, care must be taken 
in interpreting results obtained with phorbol esters (Exton, 
1988).
PKC can phosphorylate a large number of proteins in vitro 
but it is not known whether these are also physiological 
substrates for the enzyme (Nishizuka, 19 86). Addition of 
phorbol esters to perfused hearts or isolated myocytes 
results in phosphorylation of several proteins, but the 
function of these is not yet known (Katoh et al., 1981;
Presti et al., 1985; Yuan and Sen, 1986). Thus, although 
PKC has been purified from heart muscle (Kuo et al., 1984) 
much work is needed to clarify the role of PKC in vivo.
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a) Heart mechanics
Perfusion of isolated rat hearts with the phorbol 
ester 12-0-tetradecanoyl phorbol-13-acetate (TPA) has been 
shown to cause activation of PKC (Yuan et al. , 1987).
The results given in Table 3.7 show that perfusion of
-7
isolated rat hearts for 5 min. with 10 M TPA causes a 
marked decrease in developed tension and also in heart rate.
This agrees with results of Yuan et al., (19 87) who used
various phorbol esters, including an inactive analogue 
(i.e. did not activate PKC); the latter had no effect on 
heart performance indicating that the phorbol ester effects 
were due to PKC activation and not to some structural properties 
of the drugs. Addition of TPA to cultured chick myocytes 
also produces a reduced contractility (Leatherman et al.,
1987). Thus the effects of phorbol esters on heart function 
are very different to those of catecholamines and it has been 
suggested that a transient versus persistent activation
of PKC may account for these differences (Henrich and Simpson,
1988).
Exactly how PKC exerts this inhibitory effect on heart
function is not known but in vitro PKC can phosphorylate a
number of proteins involved in the contractile response in
heart e.g. troponin-I and the C-protein of the thick filament
2 +(Katoh et al., 1983), and can also modulate Ca channels 
in other cells (Rane and Dunlop, 1986; Vergilio et al.,
1986) . However, the functional significance of phosphorylation 
of these proteins by PKC in vivo (if any) is not yet understood.
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b) TGL and GPAT activities
Perfusion of hearts with a^-agonists inhibits GPAT
activity but has no effect on TGL activity (Heathers et al.,
19 85). To determine whether PKC activation would produce
similar changes, enzyme activity was measured in crude
homogenate (GPAT) or 2000g supernatant (TGL) following
-7perfusion of hearts with 10 M TPA for 5 min. Table 3.8 
shows that no change in TGL activity occurred whereas GPAT 
activity was depressed by 38%. Thus it is possible that 
PKC is indeed the mediator of the a^-induced inhibition of 
GPAT.
TPA has a vasoconstrictor effect on the heart (as 
indicated by the rise in perfusion pressure) and therefore 
may cause some degree of hypoxia or ischaemia. This is 
unlikely to be the reason for the decrease in GPAT activity 
since there is no concomittant change in TGL activity (which 
has been shown to increase during ischaemia).
Homogenates of TPA-treated hearts were then incubated 
under dephosphorylation conditions to determine whether the 
inhibition of GPAT activity could be reversed, as for 
adrenaline treated hearts. Table 3.9 shows that a partial 
restoration of activity occurred on incubation with buffer 
alone whereas a full reactivation was produced under 
dephosphorylation conditions. Therefore it appears that
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phosphorylation of GPAT occurs in response to PKC 
activation.
Heathers et al., (19 85) showed that cAMP-PrK could
inhibit GPAT and activate TGL in vitro. Purified PKC is 
not yet available commercially, but phorbol esters can 
activate PKC in vitro (Niedel et al., 1983). Heart 
extracts were therefore incubated under conditions designed 
to optimize PKC activation (Castagna et al., 1982) and 
enzyme activities determined following the incubation 
(Table 3.10). No change in TGL activity occurred, but 
GPAT activity was depressed in homogenate incubated with
-7
10 M TPA (and ATP). A further decrease in GPAT activity
2+was observed on addition of phosphatidylserine and Ca 
(which are cofactors of PKC) to the incubation. This latter 
observation strongly suggests that PKC activation is indeed 
responsible for the inhibition of GPAT.
The results discussed in this section have shown that 
GPAT activity is inhibited following either perfusion of 
hearts with TPA or incubation of heart extracts with TPA 
in vitro, whereas TGL activity is unaffected. Therefore,
PKC activation can inhibit GPAT and this inhibition can be 
reversed under dephosphorylation conditions. Whether this 
involves a direct phosphorylation of GPAT by PKC can be 
determined only when GPAT has been further purified.
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c) Effect of adrenaline and phorbol ester on the
activities of microsomal GPAT and phosphorylase
The previous section showed that perfusion of hearts with 
TPA inhibits GPAT activity in crude homogenate. Table 3.12 
indicates that this inhibition persists through isolation 
of the microsomal fraction (mitochondrial GPAT activity 
being unaffected by TPA) and is therefore a very stable 
effect. This can be compared with the effect of adrenaline 
on GPAT activity (Table 3.12). Perfusion of hearts with 
TPA and adrenaline together resulted in a similar inhibition 
of GPAT to that produced with either TPA or adrenaline alone 
(approximately 35% inhibition) indicating that the drugs do 
not act in an additive or synergistic manner.
Phosphorylase is activated by a^-agonists and recent
24-evidence using hepatocytes indicates that Ca may not be
the sole mediator of a^-induced stimulation of phosphorylase
24-(Saz et al. , 1989): in hepatocytes fully preloaded with Ga ,
a^-agonists could elicit a further stimulation of phosphorylase.
Perfusion of hearts with TPA in these experiments lead to a
40% activation of phosphorylase (Table 3.13) indicating that
PKC activation can cause phosphorylation of phosphorylase.
24-The Ca -induced activation of phosphorylase kinase and hence
phosphorylase is well known (review Hayes, 1986) and in our
24-
experiments it would have been of interest to use the Ca 
ionophore A23187 together with phorbol ester to try and 
elucidate the interactions between the two 2nd messengers.
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In liver, for example, phorbol esters alone have no effect 
on phosphorylase activity (van der Werve et al., 19 85;
Fain et al., 1984) but enhanced the activation produced 
with A23187.
The mechanism of the TPA, and hence PKC, activation 
of phosphorylase is not known. PKC is unlikely to activate 
phosphorylase kinase since, in vitro, this enzyme is not a 
substrate of PKC (Berridge, 1987) . A 2nd possibility is 
that PKC activates a phosphatase inhibitor protein which 
would increase phosphorylase activity by preventing its 
dephosphorylation. Such a mechanism has been shown for 
cAMP-PrK (Gorris et al., 1984). Whether PKC does indeed 
act on such a protein requires investigation.
Comparing the effects of TPA and adrenaline on 
phosphorylase activity shows that the stimulation by 
adrenaline is greater than that of TPA (100% v 40%),
(Table 3.12). Perfusion of hearts with TPA and adrenaline 
together resulted in a 40% activation of phosphorylase
i.e. an identical result to that obtained with TPA alone. 
Together with the observation that adrenaline has no effect 
on heart function in the presence of TPA (Table 3.11) this 
suggests that TPA inhibits the mechanical and metabolic 
responses of the heart to adrenaline. In hepatocytes phorbol 
esters have been found to inhibit the a-^-induced stimulation 
of glycogenolysis (Corvera and Garcia-Sainz, 1984) and on
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smooth muscle cells a desensitization of the a-^-receptor 
on addition of TPA has been observed (Leeb-Lundberg et al.,
1985). In addition, phorbol esters may uncouple the 
8-receptor from adenylate cyclase in some cell types 
(Kelleher et al. , 1984; Garte and Belman, 1980). We have 
shown that TPA inhibits the response of the heart to 
adrenaline, but whether TPA is acting on a^- or 8-receptors, 
or both, requires further investigation using specific 
agonists.
4.5. The diabetic myocardium
The diabetic heart contains elevated levels of triglyceride, 
free fatty acid, fatty acyl CoA and acylcarnitine (Feuvray 
et al., 1979; Paulson and Crass, 1982). Such metabolites 
have been associated with abnormal cardiac function and in 
the genesis of ischaemia and reperfusion-induced arrhythmias 
(Corr et al., 1984). Also, a higher rate of ventricular 
failure during ischaemia of diabetic rat hearts has been 
observed (Feuvray et al., 1979). Thus an understanding of 
the control of enzyme activities involved in endogenous 
lipid metabolism is an important area of investigation for 
the diabetic myocardium.
a) Heart mechanics
A depressed heart function has been observed in animal 
models of chronic (> 4 week) diabetes, this includes heart 
rate and contractility and also a ventricular Stiffening' 
(McNeill and Tahiliani, 19 86). Table 3.20 shows that in the
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model of acute diabetes employed here, heart function was 
depressed; heart rate by 30% and developed tension by 25%. 
Such impaired mechanical performance has not often been 
observed in acute diabetes. It is possible that this is 
due to the higher dose of streptozotoccin used (120mg/kg) 
compared with other workers (60 - lOOmg/kg). This would 
be expected to increase the severity of the diabetic state.
b) Effect of ischaemia and reperfusion on enzyme 
activities
During ischaemia of perfused hearts from normal rats, 
the activities of the rate-limiting enzymes for triglyceride 
hydrolysis - TGL, and synthesis - GPAT, are increased and 
decreased respectively. This has been discussed in 
Section 4.2. These changes in activity can be prevented 
by pre-perfusion of the heart with 3-adrenergic antagonists 
and are likely to be due to cAMP-dependent phosphorylation 
of the enzymes (Heathers and Brunt, 1985). On reperfusion 
of the heart, TGL activity returns to pre-ischaemic values 
indicating removal of the 8-adrenergic drive. However,
GPAT activity is further depressed. This reperfusion- 
induced fall in GPAT activity is prevented by a^-, but not 
6-, antagonists. Glycogen phosphorylase activity is also 
under the control of both and 8-receptors (Hayes, 1986) 
and adrenergic activation of phosphorylase is altered during 
diabetes (Miller, 1983; Vadlamudi and McNeill, 1983).
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CAT^ activity is not under acute adrenergic control and 
measurement of its activity can be used as an indicator 
of any general myocardial changes due to factors other 
than by these hormones.
Therefore, the activities of TGL, GPAT and phosphorylase 
(as hormonally reactive systems) and CAT^ (as a non-reactive 
system) were measured to determine whether the response of 
the enzymes to ischaemia and reperfusion was altered during 
diabetes.
i) CAT
I
No persistent effects of hormones on extracted CAT^ 
activity in any tissue have been reported. However, 
activity in brown adipose tissue was found to decrease 
in diabetes (Jamal and Saggerson, 19 88) and that of liver 
to increase (Harano et al., 1972). The liver activity also 
showed a decreased sensitivity to the physiological regulatory 
molecule of CAT^ - malonyl CoA (Cook et al., 19 84). Table 
3.2 2 shows that CAT activity was unchanged in perfused 
hearts from diabetic rats, also, there was no change in 
activity during ischaemia and reperfusion in hearts from 
both normal and diabetic animals.
ii) TGL
In diabetes, TGL activity has been reported to decrease 
in perfused rat hearts (Rosen et al., 1981; Stam et al.,
1984) but to increase in myocytes from diabetic rats
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(Ramirez and Severson, 1986). Table 3.21 shows that 
TGL activity was depressed in this model of diabetes.
This is difficult to explain in view of the increased 
lipolysis (triglyceride breakdown and glycerol release) 
observed in diabetic hearts perfused with glucose as the 
only substrate (Paulson and Crass, 1982: Rosen et al.,
1981). Ischaemia produced a greater stimulation of TGL 
activity in diabetic, compared with normal hearts (Table 
3.21). This suggests that although there is a lower level 
of basal TGL activity present in diabetes a greater 
adrenergic . drive is produced by this intervention thereby 
increasing cAMP levels.
iii) GPAT
In diabetic hearts, a 22% reduction in GPAT activity
was observed (Table 3.23). This could be caused by 
2+increased [Ca (Heyliger et al., 1987) which in turn
24-would activate Ca -dependent protein kinases to cause
inhibition of GPAT (see Sections 4.3 and 4.4). In normal
hearts, ischaemia results in a decrease in GPAT activity
which has been argued to involve cAMP-dependent
phosphorylation of the enzyme (Heathers and Brunt, 1985);
on reperfusion, GPAT activity is significantly depressed
below the ischaemic value (Table 3.23). Perfusion with 
2+both and Ca antagonists prevents the reperfusion
induced fall in GPAT activity (Heathers and Brunt, 19 85;
24-Table 3.18, this thesis). This suggests that a Ca
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dependent process is involved. Since the change in
activity is a stable one, inhibition of GPAT could be due
2+to phosphorylation by Ca -dependent kinase. Although
ischaemia causes inhibition of GPAT in diabetic hearts,
on reperfusion, no further inhibition occurs (Table 3.23).
This is in contrast to normal hearts and suggests that, in
2+diabetic hearts, Ca entry into the myocardium is impaired
2+during reperfusion. Such a decreased Ca uptake has been
reported, (Tani and Neely, 1988) and diabetic hearts are
2 +also reported to have a reduced Ca uptake on increases
2+in external [Ca ] (GjzJtzche, 1983) .
iv) Phosphorylase
Basal phosphorylase activity in diabetic hearts has 
been reported to be unchanged (Vadlamudi and McNeill, 1983) 
or slightly increased(Ingebretsen et al., 1981). Table 
3.24 shows that a highly significant increase in activity 
occurred in this model of diabetes. This result, as
2+argued for GPAT, may be explained by an increased [Ca ]^. 
This would activate phosphorylase kinase (PhK) which, in 
turn, would phosphorylate and thereby activate phosphorylase.
During ischaemia of normal hearts, an activation of 
phosphorylase was observed (Table 3.24) and on reperfusion, 
a further increase in activity occurred. These changes are 
the mirror image of the changes in GPAT activity during 
ischaemia and reperfusion and it is likely that similar
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24-mechanisms are involved i.e. cAMP-dependent and Ca -
dependent phosphorylation. On ischaemia of diabetic
hearts, phosphorylase activity was elevated but not to the
same extent as in normal hearts (Table 3.24). On reperfusion
no further activation of phosphorylase occurred. Again
this reflects the results with GPAT and would be consistent
24-with a depressed Ca entry (and hence reduced activity of 
24-Ca -dependent kinases) on reperfusion of the diabetic
24-myocardium. Such a reduced Ca uptake may have a
24-protective effect since Ca entry on reperfusion has been 
implicated as a key factor in the genesis of reperfusion-
induced arrhythmias (Jennings et al., 1985).
c) Effects of adrenaline on enzyme activity
The activities of both TGL and GPAT are under a d r e n e r g i c
control as has already been discussed (Section 4.1); TGL 
activity is increased and GPAT activity decreased on perfusion 
of the isolated rat heart with 8-agonists (Heathers et al.,
1985). In addition, GPAT activity is inhibited by a^- 
agonists.
Glycogen phosphorylase, also activated by both a^- and 
8-receptors, has been reported to have a hypersensitive 
response to 8-agonists in acutely diabetic rat hearts 
(Miller, 1983; Vadlamudi and McNeill, 1983). CAT^ activity 
is not under direct hormonal control. Therefore, we 
investigated the response to adrenaline of TGL, GPAT and 
phosphorylase (as reactive systems) and CAT^ (as a non­
reactive system) in isolated perfused hearts from diabetic 
rats.
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Table 3.2 6 shows that adrenaline produces no change 
in CATj. activity in hearts from either normal or diabetic 
rats. CAT^ . is inhibited by malonyl CoA and changes in the 
concentration of this regulatory molecule produced either 
by adrenaline or by induction of diabetes may alter the 
activity of CAT^ in vivo, this requires further investigation.
Basal TGL activity is reduced in diabetes (discussed 
in Section 4.5b). However, perfusion with adrenaline 
causes a greater stimulation of activity in diabetic hearts 
(Table 3.25). The increase in cAMP levels and protein 
kinase activity produced by adrenaline is similar in both 
normal and diabetic hearts (Miller, 1983). However, it 
has been suggested that diabetes disrupts the compartmental- 
ization of cAMP within cells (Vadlamudi and McNeill, 1983) 
since, in diabetic hearts, phosphorylase was activated 
by PGE, a compound that increases cAMP levels without 
activating phosphorylase in normal hearts. Whether this 
can explain the increased TGL activity produced by adrenaline 
in diabetic hearts remains to be investigated.
—  6Perfusion with 10 M adrenaline produced a similar
decrease in GPAT activity ( 35%) in hearts from both normal
and diabetic rats (Table 3.27) although basal GPAT activity
was depressed in diabetes. Basal phosphorylase activity
was increased by 63% in diabetes (Table 3.28) but the increase
in activity produced by adrenaline was of the same order
(two fold) in both normal and diabetic hearts. The changes
in basal activities of GPAT and phosphorylase can be explained
2+by an increased [Ca of the myocardium (Section 4.3).
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To determine whether the response of GPAT and phosphorylase 
to adrenaline is really altered in diabetes, it would be 
necessary to carry out a timecourse of the effect of 
adrenaline on enzyme activity.
As already mentioned, other workers have observed a
hypersensitive response of phosphorylase to 3-agonists in
diabetic hearts, although the increases in cAMP levels,
protein kinase activity and also phosphorylase kinase
activity were identical to those seen in normal hearts
(Miller, 1983, Vadlamudi and McNeill, 1983). Increases 
2+in [Ca or disrupted compartmentalization of cyclic
nucleotides may explain the altered response of phosphorylase, 
but this requires further investigation.
It would also be of interest to determine the response
of the enzymes to pure a^-agonists in diabetic hearts. An 
2 +altered Ca handling by the diabetic myocardium has been
reported - by both the sarcoplasmic reticulum (Lopaschuk
et al., 1983) and sarcolemma (Tani and Neely, 1988) but whether
2+the increased [Ca ]. observed with a - agonists in normal
i 1
hearts is altered in diabetes is not known. Also, there 
are no reports on the activity of PKC in diabetic hearts.
Thus much work is required to provide an understanding of 
metabolic response to adrenergic stimulation in diabetic 
hearts.
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Further work
1. Purification of GPAT and direct demonstration of 
phosphorylation using cAMP-dependent protein kinase.
2. Investigation of the interaction of the phosphorylated 
and dephosphorylated forms of TGL and GPAT with free 
fatty acids and fatty acyl CoA.
3. Investigation of the mechanism of protein kinase C- 
induced inactivation of GPAT and activation of 
phosphorylase.
4. Measurement of glycogen synthase activity during 
ischaemia and reperfusion.
5. Investigation of the effects of preperfusion with 3~ ,
2+a^- and Ca antagonists on phosphorylase and glycogen 
synthase activity during ischaemia and reperfusion.
6. Investigation of the effect of TPA on adrenergic 
receptors using specific a-^  and 3-agonists, possibly 
using cardiac myocytes.
7. Perfusion of diabetic hearts under 'diabetic'conditions 
i.e. elevated levels of fatty acids and ketone bodies, 
to determine the effect on enzyme activity.
8. Effect of perfusion on diabetic hearts with a^- and 0- 
agonists on GPAT, TGL and phosphorylase activities; time- 
course and dose dependence of the effect of such agonists on 
enzyme activity.
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